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In the peripheral sensory nervous system the neuronal expression of voltage-
gated sodium channels (Navs) is very important for the transmission of nociceptive
information since they give rise to the upstroke of the action potential (AP). Navs
are composed of nine different isoforms with distinct biophysical properties. Studying
the mutations associated with the increase or absence of pain sensitivity in humans,
as well as other expression studies, have highlighted Nav1.7, Nav1.8, and Nav1.9
as being the most important contributors to the control of nociceptive neuronal
electrogenesis. Modulating their expression and/or function can impact the shape
of the AP and consequently modify nociceptive transmission, a process that is
observed in persistent pain conditions. Post-translational modification (PTM) of Navs
is a well-known process that modifies their expression and function. In chronic pain
syndromes, the release of inflammatory molecules into the direct environment of dorsal
root ganglia (DRG) sensory neurons leads to an abnormal activation of enzymes
that induce Navs PTM. The addition of small molecules, i.e., peptides, phosphoryl
groups, ubiquitin moieties and/or carbohydrates, can modify the function of Navs
in two different ways: via direct physical interference with Nav gating, or via the
control of Nav trafficking. Both mechanisms have a profound impact on neuronal
excitability. In this review we will discuss the role of Protein Kinase A, B, and C,
Mitogen Activated Protein Kinases and Ca++/Calmodulin-dependent Kinase II in
peripheral chronic pain syndromes. We will also discuss more recent findings that the
ubiquitination of Nav1.7 by Nedd4-2 and the effect of methylglyoxal on Nav1.8 are
also implicated in the development of experimental neuropathic pain. We will address
the potential roles of other PTMs in chronic pain and highlight the need for further
investigation of PTMs of Navs in order to develop new pharmacological tools to alleviate
pain.
Keywords: voltage-gated sodium channels, post-translational modification, chronic pain, hyperexcitability,
nociceptive neurons
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PAIN, NOCICEPTION, INFLAMMATORY
AND NEUROPATHIC PAIN
The ability to recognize and remember danger is one of the
major evolutionary steps necessary for survival in a hostile
environment. The primary line of defense for organisms relies
on the primary nociceptive neurons, which are activated when
stimuli intensities reach the noxious range. The peripheral
endings of nociceptive neurons are found in almost all tissue of
the body, i.e., skin, muscle and internal organs (Kruger et al.,
2003). Their cell bodies are located in the dorsal root ganglia
(DRG) or the trigeminal ganglia (TG) for the innervations
of the face. Central terminals of primary nociceptive neurons
project to the dorsal horn of the spinal cord where they make
their ﬁrst synapse with secondary order sensory neurons and/or
interneurons (Millan, 1999). At this level, the transmission
of the signal by the secondary order projection neurons to
the supra spinal centers is modulated by a complex network
of the dorsal horn. A barrage of activity or neurotransmitter
release from the periphery can highly modulate the excitability
of the secondary order neurons (Latremoliere and Woolf,
2009). Spinal neurons are subjected to change by microglial,
astrocytic and oligodendrocitic cells (Fotia et al., 2002; Lou et al.,
2005). Furthermore, descending projections from supra-spinal
centers can aﬀect the central terminal of the primary sensory
neuron, the projection neuron and the inhibitory and excitatory
interneurons. The signal is eventually processed and reaches
supra-spinal centers, including brain areas involved in sensory
and emotional pain perception. At this point, complex circuitries
process and integrate the pain signal and allow for appropriate
behavioral and motor responses. These circuitries also modulate
pain signaling via descending pathways that ultimately reach the
dorsal horn neurons.
For the most part, primary nociceptive neurons are polymodal
(Dubin and Patapoutian, 2010), in that they are able to detect a
wide range of stimuli, such as heat and mechanical or chemical
stimuli. To integrate these wide ranges of stimuli, nociceptive
neurons express a multitude of receptors and ion channels
in their free endings (Basbaum et al., 2009). There are many
review articles that extensively discuss these so called transducers,
i.e., TRP channel family members or acid-sensing ion channels
(ASICs; Basbaum et al., 2009; Stucky et al., 2009; Deval et al.,
2010). Once transducers are activated, these non-selective ion
channels open and contribute to cell depolarization, thus eliciting
an action potential (AP) and allowing for the transmission of a
noxious signal along pain pathways.
Nociception enables the organism to react quickly, and
by virtue of the emotionally oﬀensive component of pain,
helps the organism avoid similar situations in the future.
When the noxious stimulus is acute, pain is transient and the
nociceptive neurons should subsequently return to a resting
state. This process is referred to as nociception. On the
other hand, tissue injury leads to longer lasting inﬂammatory
pain, characterized by peripheral sensitization. Inflammatory
pain is due to the modiﬁcation of the chemical environment
surrounding nociceptive neurons and the accumulation of
several factors secreted by recruited non-neural cells, such
as mast cells, macrophages, neutrophils, inﬂammatory cells,
ﬁbroblasts and keratinocytes, as well as by the nociceptive
neurons themselves. These factors are of diverse origins but
include protons (H+), nerve growth factors (NGFs), cytokines
(such as IL-1β, IL-6), tumor necrosis factor alpha (TNF-α),
prostaglandins (PGE2), several neurotransmitters (serotonin,
ATP) and peptides (bradykinin, substance P, CGRP). This
mixture is commonly referred to as “the inﬂammatory soup”
(Basbaum et al., 2009), and will increase spontaneous neuronal
ﬁring, usually decrease the threshold of nociceptive neurons
and increase ﬁring in response to suprathreshold stimuli.
The mechanisms by which inﬂammatory pain increases pain
transmission include the activation of kinases that phosphorylate
membrane channels and receptors, which subsequently alter
their function, and the genetic regulation of primary sensory
neurons (Woolf and Costigan, 1999). Inﬂammatory pain, by the
virtue of central sensitization, is also accompanied by the local
loss of inhibition (Julius and Basbaum, 2001) and enhanced
postsynaptic transmission (Galan et al., 2004).
Inﬂammatory pain is linked to the persistence of
inﬂammation, but should fade away when the tissue is healed.
In some cases, however, abnormal activity from the peripheral
neurons can also occur in the absence of tissue inﬂammation.
This abnormal activity occurs when nociceptive neurons
are damaged and elicit long-term molecular modiﬁcations
that eventually lead to neuropathic pain. Neuropathic pain
is deﬁned as the “pain caused by a lesion or disease of the
somatosensory system” (Heikamp et al., 2014). This deﬁnition
reﬂects that not only nerve injury, but also degenerative,
infectious or metabolic conditions can lead to neuropathic pain,
accounting for the distinct etiologies of peripheral neuropathic
pain (e.g., compressive disk herniation, diabetic neuropathy,
chemotherapeutic-induced neuropathy, post-herpetic neuralgia,
etc.) (Woolf and Mannion, 1999). The prevalence of neuropathic
pain varies from 7 (Bouhassira et al., 2008) to 18% of the
population (Toth et al., 2009). Most of these patients are
often resistant to treatment (Brower, 2000). Neuropathic pain
cardinal positive symptoms are spontaneous pain, allodynia
and hyperalgesia, but can be also associated with negative
symptoms such as hyposensitivity in a related nerve territory.
Spontaneous pain is thought to arise from ectopic activity, which
can be driven by C- (Djouhri et al., 2006) and A-ﬁbers (Liu
et al., 2000); where as allodynia and hyperalgesia are related
to reduced activation thresholds or an increased response
of primary aﬀerent neurons (von Hehn et al., 2012). The
peripheral mechanisms underlying neuropathic pain associated
hyperexcitability have been extensively reviewed in other articles
(Julius and Basbaum, 2001; Woolf, 2004; Campbell and Meyer,
2006; Hucho and Levine, 2007). These mechanisms include
altered gene expression, dysregulation of membrane channel
expression, migration of inﬂammatory cells and activation of
satellite cells in DRG neurons. The increased peripheral input
leads to activity-dependent mechanisms of central sensitization
in the spinal cord and supra-spinal levels (Woolf and Salter, 2000;
Latremoliere and Woolf, 2009; Woolf, 2011). Although they
share similar pain symptoms and some common mechanisms,
inﬂammatory and neuropathic pain diﬀer fundamentally by their
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respective pharmacology and resolution. Altogether, peripheral
and central mechanisms will lead to enhanced and long-lasting
pain perception, which will ultimately result in debilitating
chronic conditions, sleep disturbances, depression, anxiety and
social withdrawal (Bair et al., 2003; Turk et al., 2010). On the
other side of the spectrum, in diseases where patients can no
longer experience pain appropriately, such as in congenital
insensitivity to pain, the pain signal is permanently shut oﬀ.
This results in an inappropriate behavioral response and a
reduced life expectancy in a subset of individuals (Nagasako
et al., 2003).
Navs: STRUCTURE AND FUNCTION
After activation via transducers, primary nociceptive neurons
transmit the signal along the axon to the spinal cord. Voltage-
gated sodium channels (Navs) play a critical role in this process.
Navs are activated upon depolarization of the transmembrane
voltage, generating a fast, transient and massive inward sodium
current, which accounts for the rising phase of the AP. Navs give
rise to the upstroke of the AP and contribute to setting the resting
membrane potential of nociceptive neurons (Herzog et al., 2001;
Rush et al., 2007).
Since the ﬁrst biochemical characterization of Navs (Beneski
and Catterall, 1980), tremendous eﬀort has been made to
unravel the structure and function of the sodium channel. The
α-subunit is encoded by a single gene, which is structurally
divided into four homologous domains (I-IV) connected
by an intra and/or extracellular loop, thus referred to as
heterotetramere. Each domain is composed of six α-helical
transmembrane segments. S5 and S6 compose the pore of
the channel, whereas S1 – S4 are the voltage sensors.
The crystallography structure of NavAb, a bacterial sodium
channel from Arcobacter butzleri, was identiﬁed in 2011
(Payandeh et al., 2011). Although NavAb is a homotetramere
and the mammalian Navs is heterotetrameric, they share
similar pharmacological proﬁles (Ren et al., 2001). Most
of the inferences made based on previous biochemical and
electrophysiological experiments have been conﬁrmed (Payandeh
et al., 2011).
Nine discrete genes (SCNxA) encode for the α-subunits
(Nav1.1 to Nav1.9 isoforms) (Catterall et al., 2005) and another
atypical tenth isoform, NaX (Akopian et al., 1997; Noda
and Hiyama, 2014). Each isoform has its own biophysical
properties and particular expression pattern across the nervous
system. A single amino acid substitution in the S5–S6
linker renders Nav1.5, Nav1.8, and Nav1.9 resistance to
TTX.
α-subunits are accompanied by associated β-subunits with an
assumed stoichiometry for an α-β association of 1:1 (Catterall,
1992). There are four diﬀerent identiﬁed genes coding for the
diﬀerent β-subunits: SCN1B codes for β1 (Isom et al., 1992)
and its associated splice variant β1A (Kazen-Gillespie et al.,
2000); SCN2B codes for β2 (Isom et al., 1995a); SCN3B codes
for β3 (Morgan et al., 2000) and SCN4B codes for β4 (Yu
et al., 2003). The pore-forming α-subunit enables for Na+
conductance, but the β–subunits can modulate the biophysical
properties and plasma membrane stabilization of Navs (Isom
et al., 1995b).
Nav1.7, Nav1.8, and Nav1.9 ARE
EXPRESSED IN NOCICEPTIVE
NEURONS
Navs are broadly expressed in excitable cells throughout the
body, with some isoforms ubiquitously expressed and others
expressed in speciﬁc tissues. In nociceptive neurons, many of
the diﬀerent Navs isoforms are present and collaborate with one
another for electrogenesis. With the exception of Nav1.2 and
Nav1.4, all the Nav isoforms are expressed in DRG nociceptive
neurons (Black et al., 1996; Rush et al., 2007; Berta et al.,
2008; Fukuoka et al., 2008; Fukuoka and Noguchi, 2011; Ho
and O’Leary, 2011). The role of Nav1.5 in adult small DRG
neurons has not been fully unraveled (Renganathan et al., 2002).
As compared to Nav1.1 and Nav1.6, the Nav1.7 isoform is
the most expressed TTX-sensitive isoform among the DRG
neurons (Black et al., 1996; Toledo-Aral et al., 1997; Berta
et al., 2008; Ho and O’Leary, 2011; Dib-Hajj et al., 2013).
The two TTX-resistant isoforms, Nav1.8 and Nav1.9, are also
highly expressed in nociceptive neurons (Akopian et al., 1996;
Dib-Hajj et al., 1998). During the last decade, mutations in
Nav1.7, Nav1.8, and Nav1.9 have been linked with human pain
disorders (see Inherited Pain Syndromes). The possible variable
combinations of each of these “pain specialized” isoforms, as well
as their relative expression levels, diﬀerentially shape the AP and
ﬁring properties, accounting for the heterogeneity among DRG
neurons (Rush et al., 2007; Theriault and Chahine, 2014). In this
review, we focus on the roles of Nav1.7, Nav1.8, and Nav1.9 in
chronic pain states.
Navs’ IMPLICATION IN PAIN
SYNDROMES
Reviewing all the studies that have investigated the Nav1.7,
Nav1.8, and Nav1.9 mutations associated with painful
channelopathies and those studies that have investigated the
expression of Navs in human and animal models of pathological
pain is beyond the scope of this review and can already be found
in other recent reviews (Brouwer et al., 2014; Waxman et al.,
2014; Waxman and Zamponi, 2014; Hoeijmakers et al., 2015). In
the next two chapters we will summarize some of the key ﬁndings
demonstrating the role of Navs in channelopathies and in animal
models of inﬂammatory pain, and we will discuss conﬂicting
results observed in neuropathic pain in both human and animal
studies.
Inherited Pain Syndromes
The contribution of Nav1.7, Nav1.8, and Nav1.9 in chronic pain
syndromes is exempliﬁed through human mutations (familial
and de novo mutations) of these channels and their associated
pathologies, being either pain hypersensitivity or congenital
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insensitivity to pain (Dib-Hajj et al., 2009; Liu and Wood, 2011;
Waxman et al., 2014). Seminal studies have linked Nav1.7 to
altered pain sensitivity. A gain of function for this gene leads
to inherited painful channelopathies, such as erythromelalgia
(Cummins et al., 2004; Yang et al., 2004) and paroxysmal extreme
pain disorder (Fertleman et al., 2006). Conversely, a loss of
function for Nav1.7 was reported to be associated with congenital
insensitivity to pain (Cox et al., 2006). Many other studies have
identiﬁed Nav1.7 mutations as being implicated in numerous
altered pain sensation pathologies (Dib-Hajj et al., 2005, 2013;
Waxman andDib-Hajj, 2005; Fertleman et al., 2006; Novella et al.,
2007; Cheng et al., 2008). A gain of function mutation of Nav1.9
was linked to an episodic pain disorder (Zhang et al., 2013); while
another gain of function mutation of Nav1.9 was reported to
cause a loss of pain perception (Leipold et al., 2013). In the latter
the authors showed that the excessive activity of Nav1.9 at resting
voltages caused sustained depolarization of nociceptive neurons,
leading to the inactivation of other Navs and subsequently to the
impairment of the AP generation. Other studies also highlighted
a role of Nav1.7 in idiopathic small-ﬁber neuropathy (I-SFN);
nearly 30% of patients suﬀering from this pathology had a gain
of function mutation in Nav1.7 (Faber et al., 2012a). Small ﬁber
peripheral neuropathy is a type of peripheral neuropathy that
occurs from damage to C-ﬁbers and A-δ ﬁbers, which can often
lead to exaggerated pain sensitivity (Hoeijmakers et al., 2012).
Since these ﬁrst studies, similar gain of function mutations in
Nav1.8 and Nav1.9 have been reported in I-SFN (Faber et al.,
2012b; Han et al., 2014; Huang et al., 2014). None of the previous
gain of function mutations of Nav1.7, Nav1.8, and Nav1.9 have
been studied in animal models of chronic pain.
Acquired Pain Syndromes
Apart from intrinsic modiﬁcations of Nav channel function,
a modiﬁcation of expression levels will also impact neuronal
excitability. Most of the studies that are discussed here
investigated Nav expression while assuming that an increased
sodium channel expression and conductance would cause
neuronal hyperexcitability, something already demonstrated by
computer simulations (Matzner and Devor, 1992). However,
the link between increased sodium channel expression and
hyperexcitability is likely more complex. For instance,
computational studies revealed that increasing the sodium
conductance might actually decrease the ﬁring rate of neurons
(Kispersky et al., 2012). In addition, a gain of function mutation
of Nav1.9 was recently shown to be associated with congenital
insensitivity to pain (Leipold et al., 2013).
Modiﬁcations in Nav1.7, Nav1.8, and Nav1.9 expression have
been observed in several chronic pain syndromes. Both human
studies and experimental pain model studies have helped unravel
the role of these isoforms in chronic pain syndromes, including
both inﬂammatory and neuropathic pain.
There is substantial evidence linking Nav1.7 to inﬂammatory
pain in animal studies. Studies have reported an increase of
Nav1.7 expression after injection of pro-inﬂammatory mediators
(Gould et al., 2000; Black et al., 2004). Knocking-down Nav1.7
in a model of inﬂammatory pain with a viral vector in
primary aﬀerents (Yeomans et al., 2005) led to the attenuated
development of hyperalgesia, a result conﬁrmed by another study
using Nav1.7 knockout mice (Nassar et al., 2004). Similarly to
Nav1.7, knocking down (Khasar et al., 1998) or knocking out
Nav1.8 (Khasar et al., 1998; Akopian et al., 1999) prevented
full development of pain hypersensitivity in inﬂammatory pain
models. Nav1.8 was also shown to be increased in inﬂammatory
pain models (Coggeshall et al., 2004; Strickland et al., 2008),
and its role was conﬁrmed in knockdown studies (Yu et al.,
2011) and in studies using speciﬁc blockers (Jarvis et al., 2007;
Moon et al., 2012). Other studies also support a role for Nav1.9
in inﬂammatory pain (Dib-Hajj et al., 2010). Nav1.9 knockout
mice or knockdown rats have a weaker response to inﬂammatory
mediator application (Hirade et al., 1999; Priest et al., 2005;
Amaya et al., 2006; Lolignier et al., 2011; Hockley et al., 2014).
Dysregulated Nav expression, by altering the intrinsic
electrical properties of neuronal plasma membranes, is largely
accountable for neuropathic pain-associated hyperexcitability
(Matzner and Devor, 1994; Zhang et al., 1997). Navs’ contribution
to neuropathic pain is also demonstrated by the application
of local anesthetics known to block sodium channels, which
suppresses ectopic discharges and attenuates allodynia and
hyperalgesia (Mao and Chen, 2000; Suter et al., 2003; Scholz et al.,
2005).
The development of nerve injury-induced neuropathic pain
animal models has signiﬁcantly contributed to the discovery of
mechanisms that contribute to neuropathic pain syndromes, but
also gave rise to conﬂicting results. For instance, the role of
Nav1.7 in neuropathic pain is still being debated. Nav1.7 mRNA is
reduced after peripheral nerve injury-induced neuropathic pain
in rats (Berta et al., 2008; Laedermann et al., 2014b; Casals-Diaz
et al., 2015), an observation conﬁrmed by reduced levels of the
Nav1.7 protein. Furthermore, Nav1.7 knockout mice still develop
neuropathic pain-mediated mechanical allodynia (Nassar et al.,
2004). More recent studies suggest that Nav1.7 is actually
implicated in neuropathic pain by virtue of its concomitant
expression in both sympathetic ganglion neurons and nociceptive
neurons, rather than solely in nociceptive neurons (Minett et al.,
2012). In contrast, other studies have reported an increased
expression of Nav1.7 mRNA in DRG neurons (Liu et al., 2012),
as well as an increased protein expression in the sciatic nerve
of animal experimental neuropathic pain models (Laedermann
et al., 2013a). In humans, many studies reported an increased
expression of this isoform, such as in intervertebral disk injury
(Sadamasu et al., 2014), human dental pulp neuromas (Luo et al.,
2008b) and other neuromas (Coward et al., 2001a; Kretschmer
et al., 2002; Bird et al., 2007; Persson et al., 2011).
Nav1.8 regulation is also controversial in experimental nerve-
injury induced neuropathic pain. Many studies have reported a
downregulation of Nav1.8 mRNA (Waxman, 1999; Berta et al.,
2008), protein (Decosterd et al., 2002) and currents (Cummins
and Waxman, 1997; Berta et al., 2008) in rodent models.
Another group, however, reported an increase of the Nav1.8-
mediated current (Abdulla and Smith, 2002). To reconcile these
contradictory ﬁndings, it was suggested that a decrease in the
expression of Nav1.8 mRNA and protein in the cell soma of
nociceptive neurons could be due to a redistribution of this
isoform in the sciatic nerve (Gold et al., 2003; Thakor et al., 2009).
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Controlling Nav1.8 expression in mice also leads to controversial
results. Gene knockout studies did not ﬁnd a role for Nav1.8 in
neuropathic pain development (Akopian et al., 1999; Kerr et al.,
2001; Abrahamsen et al., 2008), whereas gene knockdown speaks
in favor of such a role (Lai et al., 2002; Dong et al., 2007; Leo et al.,
2010). It is likely that Nav1.8 involvement depends on the type of
lesion and the model of chronic pain (Joshi et al., 2006). A few
studies carried out in humans showed that Nav1.8 expression was
increased in neuromas (Kretschmer et al., 2002; Black et al., 2008;
Bird et al., 2013).
Nav1.9 implication in neuropathic pain has been scarcely
investigated. A few studies reported a downregulation of Nav1.9
mRNA and protein in animal models of neuropathic pain (Dib-
Hajj et al., 1998; Decosterd et al., 2002; Berta et al., 2008;
Laedermann et al., 2014b; Casals-Diaz et al., 2015; Yin et al.,
2015). A human study reported no modiﬁcation of Nav1.9
protein in patients with lingual nerve neuromas (Bird et al., 2013).
The conﬂicting observations of sodium channel regulation
in animal models of neuropathic pain underscores that further
research is necessary to clarify the mechanisms leading to Navs
dysregulation and to those that generate hyperexcitability. Some
of the aforementioned discrepant results can be attributed to the
use of diﬀerent models of pathological pain, the diﬀerent species
used, the relocalization of mRNA or protein, and/or various
compensation mechanisms. Some of these studies analyzed the
total pool of cellular Navs, but only Navs anchored at the
membrane regulate the electrogenesis of nociceptive neurons.
There is a large pool of intracellular Navs in the traﬃcking
pathway (Schmidt et al., 1985), and it is possible that a
modiﬁcation of the membrane fraction can be overshadowed
if one looks at the overall cellular pool of sodium channels.
Furthermore, it remains possible, that an apparent decrease of
total Nav expression in a cell is concomitant with an increase
membrane expression of sodium channels. Studying mechanisms
that regulate the traﬃcking of a channel, or mechanisms that
directly alter the biophysical properties of a channel, might
reconcile these discrepant results.
POST TRANSLATIONAL MODIFICATIONS
Both acquired and inherited pain syndromes are manifestations
of altered function and expression of Navs that result in electrical
instabilities in the nociceptive pathway, ultimately leading to
pathological pain. In channelopathies, the pain syndrome is due
to a DNA mutation that can be either sporadic or inherited. In
acquired pain syndromes, the altered expression and function can
be due to a plethora of signaling pathway activations. Among
them, post-translational modiﬁcations (PTMs) are important
contributors to the development of chronic pain syndromes.
Post-translational modiﬁcations are protein modiﬁcations
that occur either soon after the ribosome-mediated translation
of the mRNA into a polypeptide chain or later in the secretory
pathway. These are critical steps for protein maturation
and function. In these processes, many diﬀerent enzymes
attach biochemical groups (acetylation, phosphorylation),
polypeptides (ubiquitylation, SUMOylation) and complex
molecules (glycosylation, isoprenylation), or cleave (proteolysis)
a protein’s speciﬁc amino acid. The overall eﬀect of PTMs leads
to a modulation of the structure, function or localization of the
given protein. PTMs were ﬁrst identiﬁed in the study of kinases
(Hunter, 2009) and protein degradation (Ciechanover, 2005;
Kresge et al., 2006) many decades ago. Since then the number of
diﬀerent PTMs has risen to over 200 (Mann and Jensen, 2003).
PTMs are involved in almost every cellular event, from precise
gene expression regulation to broad signal integration (Deribe
et al., 2010).
Post-translational modiﬁcations have a large spectrum of
action on proteins, ranging from very stable modiﬁcations to very
transient and reversible changes. For instance, glycosylation and
disulﬁde bridge formation are directly implicated in the synthesis,
maturation and folding of the protein. The covalent binding of
molecules, such as the addition of a ubiquitin moiety, leads to
quicker and stable protein modiﬁcation. On the other side of
the spectrum, some PTMs are versatile and are important for
transient cellular signaling, as exempliﬁed by the phosphorylation
process.
There is precise coupling between the interaction sites of
PTMs and a given amino acid sequence on the target protein,
rendering the system very speciﬁc. This also allows for good
spatial (many diﬀerent amino acids can be targeted by the same
PTM) and temporal (a given amino acid can be modiﬁed by
diﬀerent PTMs) control and allows neurons to ﬁne tune the
properties of a protein depending on the changes occurring in
the direct environment.
PTMs ALTER Nav FUNCTION AND/OR
EXPRESSION
Computational studies have shown that, depending on the site
of phosphorylation, the addition of a phosphoryl group that
carries two negative charges at physiological pH (Narayanan and
Jacobson, 2009) can modify the structure and the function of the
protein through an alteration of the free energy landscape. Navs
possesses charged residues in the voltage sensor domain that can
sense membrane potential oscillation. When the transmembrane
voltage changes, these charged domains reorient in the electric
ﬁeld resulting in conformational changes, a process referred
to as gating. The addition of charged groups on their intra-
cellular, extra-cellular or transmembrane domains modiﬁes
protein intrinsic properties and functions. Apart from the direct
electrostatic eﬀect on gating of the channels, phosphorylation
can also create or disrupt binding sites for interaction with other
regulatory proteins that modulate Nav function.
Navs need to be at the interface between a high extracellular
and low intracellular sodium concentration to open and drive
sodium inﬂux. For this reason they are only functional when
anchored at the plasma membrane. There is also, however, a
large intracellular pool of Navs in the secretory pathway of the
cell (Schmidt et al., 1985; Ritchie et al., 1990). A tight balance
between the membrane and the intracellular pool, a process
referred to as traﬃcking, is crucial for the ﬁne-tuning of cellular
excitability in nociceptive neurons. Maintaining this equilibrium
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is largely mediated by PTMs that regulate the traﬃcking of Navs
(Cusdin et al., 2008). Some enzymes will generate PTMs that
are responsible for internalization and/or degradation, whereas
others will promote externalization or stabilization of Navs at the
membrane.
PERIPHERAL SENSITIZATION
TRIGGERS PTMs
We previously highlighted that peripheral sensitization is
triggered by the inﬂammatory soup (Basbaum et al., 2009).
There is a large body of evidence that there is a recruitment
of macrophages (Perry et al., 1987) and neutrophils (Daemen
et al., 1998), as well as degranulation of mast cells (Olsson,
1967; Zochodne et al., 1994) in inﬂammatory processes, such
as the ones observed after nerve injury. Once recruited, these
cells secrete peptides, such as prostaglandins (PGE2), bradykinin,
NGF and serotonin (Cesare et al., 1999; Petho and Reeh, 2012).
They also secret cytokines, such as TNF-α or IL-1β and IL-6
(Wells et al., 1992). Some of these mediators are not only secreted
by immune or inﬂammatory cells, but also by the nociceptive
neurons themselves (Daemen et al., 1998). When inﬂammation
resolves, these molecules are slowly cleared from the extracellular
liquid around nociceptive neurons. In some cases, however, pro-
nociceptive molecules, such as NGF and cytokines, (Leung and
Cahill, 2010; Dogrul et al., 2011; Gaudet et al., 2011) are found
to persist at the site of injury. This phenomenon may partially
explain any long-term changes.
When binding to receptors, which include neurotrophic
tyrosine kinase receptors (NTKR), such as TrkA, and/or
G-protein coupled receptors (GPCRs), such as bradykinin and
PGE2 receptors, these aforementioned ligands (peptides and
cytokines) will activate multiple intracellular pathways, including
Protein Kinase A (PKA), Protein Kinase B (PKB), Protein
Kinase C (PKC), Mitogen-activated protein Kinase (MAPK) and
the Ca++/Calmodulin-dependent Kinase I and II (CamKI/II),
among others (Figure 1). The concrete, but not sole, eﬀect of
these cascades is phosphorylation or other PTMs of Navs (Dib-
Hajj et al., 2010), which lead to long-term increased neuronal
excitability. It should, however, be noted that PTMs also control
other ion channels, such as potassium channels, and even
modulate the activation of some transcription factors. Theymight
also regulate nociceptive neuronal excitability through these
alternative mechanisms.
PROTEIN KINASES
Phosphorylation is an important PTM that aﬀects up to 30%
of proteins in vivo (Kreegipuu et al., 1999). The phosphate
group is usually added to serine, threonine, histidine, and
tyrosine residues in eukaryotic proteins. The eﬀect of protein
kinases (PKs) on Navs in peripheral chronic pain syndromes
has been extensively reported in the literature. The reports are
varied and complex, largely due to the important number of
phosphorylation sites and to the large number of diﬀerent PKs
present in nociceptive neurons. PKs can modulate Nav function
in a very short-term range upon electrostatic interferences.
Phosphate groups carry a −2 charge at physiological pH that
might interfere with the Navs voltage-sensing domain, or other
domains implicated in the gating of the channel. PKs can also
have long-term eﬀects when regulating Nav traﬃcking, which is
acheived by masking or highlighting targeting sequences, such as
the endoplasmic reticulum (RE) retention signal of Navs (Zhou
et al., 2002).
Protein Kinase A
The immediate increase in nociceptive neuronal excitability
observed after tissue injury or inﬂammation results from
G-protein-coupled receptor activation and the resulting
intracellular signaling pathway (Woolf and Costigan, 1999).
G-protein binding leads to an increase in cAMP production
by adenylate cyclase (AC), which ultimately activates PKA.
Triggering of this pathway by direct cAMP application or
activation of AC is suﬃcient to elicit hyperalgesia in animals
(Taiwo et al., 1989; Kress et al., 1996; Hucho and Levine, 2007).
PKA activation not only plays a role in the initiation of pain
hypersensitivity, but is also important for the maintenance of
inﬂammatory pain (Aley and Levine, 1999). PGE2 is one of the
best-known ligands that activates this pathway. PGE2 binds to the
prostaglandin E2 receptor (E2) and increases cAMP in sensory
neurons (Pierre et al., 2009). Many studies have reported that
PGE2-induced hyperalgesia is due to PKA activation (Pitchford
and Levine, 1991; Khasar et al., 1995; England et al., 1996).
Protein kinase A phosphorylates Nav1.2 in brain neurons
(Costa and Catterall, 1984a; Rossie and Catterall, 1987), with the
main eﬀect being a 50% reduction in the peak current (Gershon
et al., 1992), along with modiﬁcations of some biophysical
properties (Li et al., 1992; Smith and Goldin, 1996). This suggests
that both the function and expression of Nav1.2 are modiﬁed
by PKA. Since these early studies, other groups have reported
similar decreases in Nav1.1, Nav1.6, and Nav1.7 in diﬀerent
cell expression systems and intact cells (Gershon et al., 1992;
Cantrell et al., 1997; Smith and Goldin, 1998; Zhou et al., 2000;
Vijayaragavan et al., 2004a; Chen et al., 2008; Liu and Zheng,
2013). The phosphorylation sites of Nav1.2 by PKA were mostly
investigated using traditional biochemical approaches (Murphy
et al., 1993; Smith and Goldin, 1996; Cantrell et al., 1997).
A lot of new predictive bioinformatic tools have helped identify
phosphorylation sites on other isoforms.
Protein kinase A is increased after inﬂammation and in
pathological pain states. Vijayaragavan et al. (2004a) showed
that PKA decreases Nav1.7. One could hypothesize, therefore,
that inﬂammation may decrease nociceptive neuronal excitability
through Nav downregulation. However, Nav1.7, as well as other
Nav isoforms, can undergo alternative splicing, with each splice
variant possessing distinct biochemical and pharmacological
properties (Schaller et al., 1992; Plummer et al., 1997; Dietrich
et al., 1998; Schirmeyer et al., 2014). It was previously shown that
a particular Nav1.7 splice variant, Nav1.7 11S, was upregulated
and responsible for pain hypersensitivity in animal models
of neuropathic pain (Raymond et al., 2004). Contrary to the
lack of eﬀect of PKA on three spice variants, the Nav1.7 11S
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FIGURE 1 | Scheme representing the peripheral terminal, axon and cell soma of a pseudo-unipolar dorsal root ganglia nociceptive neuron, in normal
and pathological pain conditions. Following tissue damage and inflammation, recruited inflammatory cells secrete numerous pro-inflammatory molecules (referred
to as the inflammatory soup). These chemical mediators activate many membrane proteins, including G-protein coupled receptors (GPCR), neurotrophic tyrosine
kinase receptors (NTKR) and cytokines receptors (CR). GPCR binding by PGE2 and bradykinin mostly leads to protein kinase A (PKA) and protein kinase C (PKC)
activation, through the adenylate cyclase (AC) and inositol 3-phosphate (IP3) secondary messengers, respectively. NTKR and CR binding by TNFα, IL-6 and NGF will
activate ERK1/2 and p38 kinases via different potential secondary messengers. These signal transduction pathways can undergo cross communication one with
another. In experimental neuropathic pain, nerve injury induces Nedd4-2 downregulation. In models of diabetic neuropathy, as well as in patients, methylglyoxal
accumulation is related to an increased glucose concentration. The increased activation of kinases, the downregulation of Nedd4-2 and the accumulation of
methylglyoxal all lead to an increase of Nav1.7/Nav1.8 function (shift of biophysical properties, making the channel more available, as represented in green and red in
the figure) and/or to an increase of Nav1.7/Nav1.8 expression at the membrane (altered trafficking), which leads to increased sodium influx and consequently to
nociceptive neuronal hyperexcitability.
splice variant activation curves were shifted to hyperpolarized
potentials upon PKA activation, thus lowering the threshold
for opening of the channel and presumably increasing neuronal
excitability (Chatelier et al., 2008). The current hypothesis is that
in chronic pain syndromes the increase of this splice variant,
together with the modiﬁcation of its biophysical properties by
PKA, will lead to an increase in sodium conductance which
results in nociceptive neuronal hyperexcitability. One must keep
in mind that the eﬀect of PKA on Nav1.7 was found in Xenopus
oocytes and other mammalian cell lines, which have a diﬀerent
cellular background than nociceptive neurons, and that Nav
regulation varies greatly depending on cell type (Cummins et al.,
2001). This is highlighted by one Nav1.7 mutation that renders
DRG sensory neurons hyperexcitable, but decreases sympathetic
DRG neuron excitability (Rush et al., 2006). Studying an
endogenous Nav1.7 current in adrenal chromaﬃn cells revealed
that cAMP upregulates Nav1.7 (Yuhi et al., 1996). Thus, a
careful characterization of PKA’s eﬀect on the Nav1.7 current in
nociceptive neurons needs to be performed.
The eﬀect of PKA on TTX-resistant isoforms is the opposite
to that aforementioned. PKA increases the TTX-resistant current
(Gold et al., 1996, 1998) in DRG neurons, an eﬀect at least
partially due to PGE2 (England et al., 1996). A similar increase in
the Nav1.8 current isolated from a recombinant protein expressed
in Xenopus oocytes (Vijayaragavan et al., 2004a) and mammalian
cells (Fitzgerald et al., 1999) was also reported, providing
evidence that PKA activation in pathological pain states can
generate nociceptive hyperexcitability through enhanced Nav1.8
expression and function. How PKA increases the Nav1.8 current
is partially due to increased membrane traﬃcking, since blocking
protein transports in DRG neurons prevented a PKA-induced
increase of the Nav1.8 mediated current (Liu et al., 2010).
Furthermore, using a site-directed mutagenesis approach, the
authors proposed that the forward traﬃcking eﬀects of Nav1.8
could be due to the phosphorylation of an identiﬁed ER retention
signal.
Nav1.9 is also increased by inﬂammatory mediators (Maingret
et al., 2008), such as PGE2. This mechanism is dependent on
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G-protein activation (Rush and Waxman, 2004) and GTPγS
(Vanoye et al., 2013).
Protein Kinase B
The PKB (also referred to as Akt) is well-known for its role in
neuronal plasticity in the brain (Sanna et al., 2002), but little
is known about its role in the pain ﬁeld. There is evidence,
however, that PKB is activated in sensory neurons in animal
models of neuropathic pain (Xu et al., 2007a; Shi et al., 2009)
and inﬂammatory pain (Zhuang et al., 2004; Sun et al., 2006).
Furthermore, intrathecal injection of a PKB inhibitor attenuated
formalin and carrageenan-induced hypersensitivity (Xu et al.,
2011). The authors demonstrated that this eﬀect was due to
mTOR signaling in the spinal cord, but the intrathecal injection
mode of delivery cannot rule out an additional eﬀect in the
peripheral nervous system. A recent study showed that PKB
activation in peripheral sensory neurons was necessary for the
inﬂammatory-induced increased expression of both Nav1.7 and
Nav1.8 (Liang et al., 2013) since blocking this kinase reversed
the upregulation of both isoforms. The previous study did not
demonstrate that PKB could directly phosphorylate Navs, nor
has any other study to our knowledge. However, ASICS, another
important ion channel implicated in pain processing, can be
directly phosphorylated by PKB, leading to increased traﬃcking
and enhanced expression of ASICs at the membrane (Duan et al.,
2012). Further investigations are required to unravel the role of
PKB in the phosphorylation of Nav channels in pathological pain.
Protein Kinase C
The implication of PKC activation in nociceptive neurons has
been extensively studied. Activation of PKC by phorbol esters
demonstrated an in vivo implication of this pathway in peripheral
sensitization (Rang and Ritchie, 1988; Schepelmann et al., 1993;
Souza et al., 2002). PKC inhibition decreased hyperalgesia in a
model of diabetic neuropathy. Together with PGE2, bradykinins
are also able to activate PKC pathways (Cesare and McNaughton,
1996; Ferreira et al., 2005, 2008). PKC is a serine/threonine kinase,
which has at least 12 diﬀerent isoforms (Way et al., 2000) that
can be classiﬁed into diﬀerent groups (Battaini, 2001). PKCε is
one of the isoforms shown to be necessary for the development
of hypersensitivity in animal models of peripheral chronic pain
(Khasar et al., 1999; Aley et al., 2000; Dina et al., 2000, 2001).
Inﬂammatory molecules enhance the translocation of PKCε to
the membrane, where it contributes to peripheral sensitization
(Khasar et al., 1999; Hucho and Levine, 2007; Zhang et al., 2007).
Other PKC isoforms have also been implicated in chronic pain,
but focus has been on their expression in the spinal cord.
As for PKA, the phosphorylation of Nav1.2 by PKC (Costa
and Catterall, 1984b) could be responsible for a reduction of
up to 80% of the current when expressed in Xenopus oocytes,
with a concomitant slowing of its inactivation (Numann et al.,
1991). This reduction is due, at least in part, to a positive
shift in the voltage-dependence of activation (Dascal and Lotan,
1991). Similar ﬁndings on the total sodium current have been
observed in rat brain neurons (Numann et al., 1991; Cantrell
et al., 1996). Other studies in Xenopus oocytes have shown
that PKC downregulates the skeletal muscle sodium channel
Nav1.4 (Bendahhou et al., 1995), the cardiac channel Nav1.5
(Murray et al., 1997), as well as the two pain specialized isoforms
Nav1.7 and Nav1.8 (Vijayaragavan et al., 2004a). It was initially
hypothesized that PKC robustly downregulates Navs across
species since a reduction in the Nav1.5 current was also observed
in myocytes and CHO cells (Qu et al., 1994), and a reduction
in the total sodium current was observed in neuroblastoma cells
(Renganathan et al., 1995), hippocampal neurons (Cantrell et al.,
1996), and cortical neurons (Mittmann and Alzheimer, 1998).
As with PKA activation, the decrease of the Nav1.7
current mediated by PKC activation (Vijayaragavan et al.,
2004a) is discrepant with the increased excitability observed
in pathological pain. Again, the cellular background studied
could explain these discrepancies. Furthermore, a study reported
that blocking PKC phosphorylation was concomitant with
a decrease in Nav1.7 protein expression upon continuous
opioid administration in a diabetic painful neuropathic model
(Chattopadhyay et al., 2008). In addition, a recent study also
showed that PMA activation of PKC pathways led to an increase
of Nav1.7 resurgent currents in HEK cells (Tan et al., 2014),
currents which have been implicated in pathological pain (Jarecki
et al., 2010).
Gold et al. (1996, 1998) observed that the activation of PKC
increased the TTX-resistant current in nociceptive neurons. This
was later conﬁrmed by another group (Ikeda et al., 2005). A later
study determined which PKC isoform and which of the two TTX-
resistant isoforms were responsible for the increased current,
implicating PKCε and Nav1.8 (Cang et al., 2009). The PKCε
mediated upregulation of Nav1.8 was conﬁrmed in another study,
demonstrating the causative link to hyperalgesia (Wu et al.,
2012). Since PGE2 can activate the PKC pathway and increase
the Nav1.9 current in nociceptive neurons (Rush and Waxman,
2004), it is likely that both Nav1.8 and Nav1.9 are implicated.
Nav1.8 and Nav1.9 are well-identiﬁed sodium channels whose
expression and function are increased upon pathological pain-
driven PKC activation. The role of Nav1.7, however, remains
to be fully elucidated. Since PKA and PKC pathways converge
and co-regulate Nav1.2 function (Chahine et al., 2005), similar
mechanisms might also account for the eﬀects on Nav1.7, Nav1.8
(Gold et al., 1998) and Nav1.9.
MAPK Pathway
Mitogen-activated protein kinases are another family of kinases
that play an important role in mammalian cell signaling. There
are three major members in the MAPK family: ERK, p38 and
c-JUN. Each member activates a speciﬁc intracellular pathway
(Widmann et al., 1999). They regulate various cellular activities
and have been implicated in numerous human diseases, including
tissue injury (Kim and Choi, 2010). Since they are activated by
proinﬂammatory cytokines (Ji et al., 2009), they have been shown
to be important in pathological pain (Obata and Noguchi, 2004).
In transected axons of experimental neuromas, Nav1.7
accumulates with ERK1/2 at the site of injury (Persson et al.,
2011). Since ERK1/2 was shown to phosphorylate Nav1.7,
altering its biophysical properties and rendering it easier to
open in response to stimuli (Stamboulian et al., 2010), it is
hypothesized that a Nav1.7 and ERK1/2 co-accumulation would
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increase nociceptive neuronal ﬁring. Another study proposed
that IL-6 application enhances the excitability of trigeminal
ganglion neurons via ERK-mediated phosphorylation of Nav1.7,
a mechanism involved in the development of migraine-related
pain behavior (Yan et al., 2012).
Another kinase of the MAPK, p38, was reported to be
increased in animal models of neuropathic pain (Obata and
Noguchi, 2004; Xu et al., 2007b), leading to the upregulation
of TTX-resistant sodium channels in sensory neurons (Jin
and Gereau, 2006). A study recently unraveled the role of
TNF-α in activating p38, resulting in the modiﬁcation of
the slow inactivation and voltage dependence of activation of
Nav1.8/Nav1.9. This, in turn, increases the TTX-resistant inward
current and enhances nociceptive hyperexcitability (Gudes et al.,
2015). Another study showed that p38 phosphorylates Nav1.8,
increasing the traﬃcking of this channel at the membrane of DRG
neurons (Hudmon et al., 2008).
Similar to the previous studies investigating MAPK activation
in animal models of chronic pain and those focusing on the
regulation of Nav1.7 and Nav1.8 by kinases in vitro, ERK1/2 and
p38 are increased along with the Nav1.7 and Nav1.8 isoforms in
painful human neuromas (Black et al., 2008), where they likely
also contribute to neuronal hyperexcitability.
CamKII
Calmodulin (CaM) is a small calcium-binding protein that senses
Ca2+ changes and drives cellular responses to rapid changes
in intracellular calcium concentration. It is also known to be
involved in regulating Ca2+-dependent neuronal plasticity (Solà
et al., 2001).
The C-terminus of Navs contains a CaM-binding domain,
known as the IQ motif (Mori et al., 2000), which is a
recognizable site for these calcium-sensing proteins. Even though
the functional meaning of such binding remains unknown, there
are a few studies reporting the regulation of Nav currents by
CaM. Despite the fact that all Navs possess a conserved IQ motif,
the regulatory eﬀect of CaM is isoform speciﬁc, as exempliﬁed by
the more potent regulation of Nav1.4 as compared to Nav1.5 by
this protein (Deschênes et al., 2002; Young and Caldwell, 2005;
Biswas et al., 2008; Ben-Johny et al., 2014). CaM also regulates
Nav1.6, which is expressed in nociceptive neurons (Herzog et al.,
2003). Interestingly, Nav1.7 is also bound by CaM (Herzog et al.,
2003), but with a lower aﬃnity than Nav1.6.
CaM Ca2+-dependent activation leads to the activation of
many signaling molecules, one being the Ca2+/CaM-dependent
serine/threonine kinase (CamK) (Nelson and Chazin, 1998).
CamKII is expressed in nociceptive neurons and is involved in
pain transmission (Hiruma et al., 1999; Brüggemann et al., 2000).
It was proposed that CamKII is responsible for the transition
from acute to chronic pain, a process involving PKCε activation
(Ferrari et al., 2013) and links these two kinase pathways. Further
evidence supporting a role for CamKII in neuropathic pain
was demonstrated by using a CamKII inhibitor that reversed
mechanical allodynia in animal models of both neuropathic pain
(Chen et al., 2009) and inﬂammatory pain (Luo et al., 2008a).
Since the CaM binding eﬀect on Navs regulation is thought
to be due to the recruitment and subsequent phosphorylation of
Navs by CamKII (Deschênes et al., 2002; Maltsev et al., 2008),
it is likely that the activation of this kinase in pathological pain
states is partially responsible for hyperexcitability through the
regulation of Nav. This hypothesis remains to be conﬁrmed.
GLYCOSYLATION
Glycosylation is another important PTM that aﬀects sodium
channel function and expression. Glycosylation is a crucial step
for protein biosynthesis and folding, but it is also involved in
cell signaling, cell-cell adhesion, protection against proteolysis,
and cellular development and immunity (Moremen et al., 2012).
Nav α-subunits undergo important glycosylation steps in the
endoplasmic reticulum and Golgi apparatus (Waechter et al.,
1983; Schmidt and Catterall, 1987), a process involving the
sequential addition of N-acetylglucosamines capped by sialic
acid residues, and the further addition of diverse oligosaccharide
chains. Glycosylation can account for 5% (Cohen and Barchi,
1993) to 30% of the α-subunit’s molecular weight (Messner and
Catterall, 1985), depending on the isoform, with an estimated
stoichiometry of around 100 sialic acid molecules per channel
(James and Agnew, 1987). Glycosylation is known to inﬂuence
Nav gating properties (Recio-Pinto et al., 1990; Bennett et al.,
1997; Zhang et al., 1999; Tyrrell et al., 2001) by interfering
with the electric ﬁeld near the gating sensors (Bennett et al.,
1997; Cronin et al., 2004). It was proposed that extracellular
sialic acid residues, which are negatively charged at physiological
pH, inﬂuence the sensitivity of the voltage sensor domains to
the transmembrane electrical potential diﬀerence (Ednie and
Bennett, 2011).
Only a few studies have investigated glycosylation of Navs in
the peripheral sensory nervous system. One reported that Nav1.9
is subject to important developmentally regulated glycosylation.
This isoform is found in two diﬀerent heavily glycosylated
forms in neonatal rats, which have diﬀerent gating properties
as compared to the less glycosylated form of Nav1.9 in adult
tissue (Tyrrell et al., 2001). Another study reported that Nav1.7 is
found in at least two diﬀerent glycosylated forms in HEK293 cells:
a heavily functional glycosylated form and a core-glycosylated
immature form (Laedermann et al., 2013a). The same authors
later reported that a third intermediate glycosylated form is also
present in HEK293 cells (Laedermann et al., 2013b). Inhibition
of glycosylation in Xenopus oocytes by tunicamycin also altered
Nav1.3 gating properties (Xu et al., 2008). Whether these diﬀerent
patterns of α-subunit glycosylation lead to modiﬁcation of Nav
function has yet to be investigated in peripheral chronic pain
syndromes.
UBIQUITYLATION
Ubiquitylation is another well-known PTM that negatively
regulates the cell surface expression of many diﬀerent plasma
membrane proteins (Staub and Rotin, 2006). Ubiquitylated
proteins that are internalized through this pathway are either
degraded or recycled (Shih et al., 2000; Abriel and Staub, 2005;
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Ciechanover, 2005). Ubiquitin is a small and highly conserved
polypeptide of 76 amino acids that is covalently attached to
the lysine residues of the targeted protein. Three enzymatic
successive steps are required to ubiquitylate a protein (Pickart,
2001): (1) ubiquitin is ﬁrst activated by a ubiquitin-activating
enzyme (E1) in an ATP-dependent manner, (2) ubiquitin is then
transferred to a ubiquitin-conjugating enzyme (E2) via a thioester
bond, (3) this complex further interacts with an ubiquitin-protein
ligase (E3) that eventually ubiquitylates the substrate protein.
The ﬁrst and probably best-described protein that undergoes
ubiquitylation is ENaC (Abriel et al., 1999; Rossier et al., 2002).
The ENaC subunit possesses a PY motif. Mutating this motif is
suﬃcient to generate a hypertensive phenotype, known as Liddle’s
Syndrome (Schild et al., 1996), which involves increased ENaC
function (Firsov et al., 1996). Nedd4 and Nedd4-2 proteins where
shown to bind to ENaC’s PY motif on large members of the E3
ubiquitin ligase family (Joazeiro and Weissman, 2000; Metzger
et al., 2012), leading to its internalization (Abriel et al., 1999;
Henry et al., 2003). This process is impaired in Liddle’s syndrome.
Most Navs possess a PY motif at their α-subunit C-terminal,
making them potential substrates for Nedd4-2 dependent
ubiquitylation (Abriel et al., 2000; Laedermann et al., 2014a).
The ﬁrst sodium channel isoform described to be regulated
by Nedd4-2 was Nav1.5. Regulation was demonstrated in both
cell expression systems and cardiac tissue (van Bemmelen et al.,
2004). Nav1.7 and Nav1.8 also possess a PY motif and were
shown to be negatively regulated by Nedd4-2 in both Xenopus
oocytes (Fotia et al., 2004) and HEK293 cells (Laedermann et al.,
2013a). The functional signiﬁcance of Nav regulation by Nedd4-2
was previously demonstrated in chronic pain syndromes. In an
animal model of neuropathic pain, ubiquitin ligase expression
was robustly reduced in both mice (Laedermann et al., 2013a)
and rats (Cachemaille et al., 2012). Nav1.7 and Nav1.8 expression
were increased as a consequence of Nedd4-2 downregulation.
The causal link between Nedd4-2 downregulation and Nav1.7
/Nav1.8 upregulation was demonstrated using both tissue speciﬁc
knockout and viral overexpression of Nedd4-2, leading to hyper-
and hypo- pain sensing phenotypes, respectively (Laedermann
et al., 2013a). The reduction of Nedd4-2 might also increase
membrane expression of other Navs, with the exception of Nav1.9
which lacks the PY motif, (Abriel et al., 2000), and other ion
channels expressed in sensory neurons that are also substrates
for this ubiquitin ligase (Bongiorno et al., 2011). Nav1.6 was also
regulated by Nedd4-2 in mouse hippocampal neurons, a process
dependent on the concomitant p38-mediated phosphorylation
of this sodium channel isoform (Gasser et al., 2010). Whether
Nedd4-2 downregulation in neuropathic pain is due to the
inﬂammatory soup or to another mechanism remains to be
investigated.
METHYLGLYOXAL
A recent study unraveled a new mechanism accounting
for painful peripheral neuropathy in diabetes. The authors
showed that the concentration of methylglyoxal, an endogenous
degradation product of excessive glycolysis (Thornalley, 2005),
is increased in patients suﬀering from diabetes. Since peripheral
nerves have low levels of enzymes that metabolize methylglyoxal
(Bierhaus and Nawroth, 2009), its accumulation in the sensory
system was proposed to account for pain hypersensitivity. The
authors reported that the methylglyoxal eﬀect on excitability was
through its binding to Nav1.8 within the DIII-DIV linker on an
arginine residue, which reduced channel inactivation (Bierhaus
et al., 2012), leaving the channel in an excitable state. In sciatic
nerve biopsies isolated from patients with diabetes and from
those who had amputations due to peripheral artery disease,
the authors observed an increase of Nav1.8 modiﬁcation by
methylglyoxal when compared to controls. It was proposed that
this PTM was speciﬁc to Nav1.8 in regards to sodium channel
regulation, but the authors demonstrated that methylglyoxal
can also have an eﬀect on pain pathways by depolarizing
nociceptive neurons, and increasing GCRP release and COX-2
expression.
POST-TRANSLATIONAL MODIFICATION
OF Nav PROTEIN PARTNERS
Many protein partners are known to interact with typical
pain isoforms and undergo PTM. Evidence is lacking which
demonstrates a direct eﬀect between protein partners’ PTMs and
concomitant modiﬁcation of Nav expression or function. In the
following chapter, we will discuss the potential partners that
undergo PTMs that are known to regulate Nav1.7, Nav1.8, and
Nav1.9.
β–Subunits
β–subunits are important regulators of Navs. They are implicated
in neuropathic pain and are subject to PTMs. β-subunits regulate
α-subunit gating properties by direct steric interactions that
interfere with the voltage-sensor (Zimmer and Benndorf, 2002).
Even though the eﬀects of the diﬀerent β-subunits on biophysical
properties give rise to conﬂicting results (Nuss et al., 1995;
Sangameswaran et al., 1997; Smith and Goldin, 1998; Morgan
et al., 2000; Fahmi et al., 2001; Vijayaragavan et al., 2001, 2004b;
Zimmer and Benndorf, 2002), partially due to the diﬀerent cell
types used, the literature clearly demonstrates that β-subunits
regulate Nav gating. β-subunits can also aﬀect the Nav current
in an ex vivo nociceptive neuron primary culture, as highlighted
by the decreased INa current recorded from SCN1B and SCN2B
knockout animals (Lopez-Santiago et al., 2006, 2011). SCNB
knockout animals also demonstrated abnormal pain sensing,
conﬁrming that modulating Nav function ultimately modulates
pain signaling (Pertin et al., 2005; Lopez-Santiago et al., 2006,
2011). Moreover, β1-, β2-, and β3-subunit expression levels are
increased in diﬀerent animal models of pathological pain (Shah
et al., 2000; Coward et al., 2001b; Pertin et al., 2005), highlighting
their potential implication in modulating cellular excitability.
Auxiliary β-subunits are themselves substrates for glycosylation
(Isom et al., 1992), which ultimately modulates α-subunit
function (Johnson et al., 2004; Johnson and Bennett, 2006).
β-subunits can also be phosphorylated, i.e., the phosphorylation
of Tyr181 is necessary for the interaction with ankyrin, another
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Nav protein partner (Malhotra et al., 2002). Whether altered
glycosylation or phosphorylation of the β-subunits could be
implicated in pathological pain has, at least to our knowledge,
never been investigated.
Nedd4-2
Nedd4-2, a potent regulator of Navs in the sensory nervous
system, also undergoes several PTMs, particularly by kinases
which alter its function. Most of these pathways have been
investigated in the Nedd4-2 regulation of ENaC (Snyder, 2009).
Whether a similar action also occurs on the sodium channels
in the sensory system remains to be determined. Pathways that
lead to Nedd4-2 PTMs are the same pathways as those activated
in chronic pain syndromes. For instance, phosphorylation of
Nedd4-2 by PKA was demonstrated to decrease Nedd4-2
ubiquitylating eﬃciency (Snyder et al., 2004). In addition to its
direct eﬀect on Navs, it is probable that PKA activation also
indirectly leads to an increase of Nav channels at the membrane
by impeding the downregulatory role of Nedd4-2. It has been well
documented that cytokine signaling leads to NF-κB activation
in inﬂammatory processes. These signals ﬁrst activate the IκB
kinase [an inhibitor of nuclear factor κB (NF-κB)] (IKK) via
phosphorylation, which then phosphorylates and inactivates IκB
inhibitory proteins. IKKβ, a subunit of IKK that is expressed
in unmyelinated ﬁbers, then binds and phosphorylates Nedd4-
2 (Edinger et al., 2009). Finally, NGF, another inﬂammatory
mediator (Leung and Cahill, 2010) also known to positively
regulate Navs mRNA expression (Toledo-Aral et al., 1997; Fjell
et al., 1999), triggers a cascade after binding to the TrkA receptor,
which ultimately leads to Nedd4-2 phosphorylation (Arévalo
et al., 2006). Pro-inﬂammatory molecules likely negatively
regulate Nedd4-2 activity in nociceptive neurons following
inﬂammation, leading to an increase in Nav expression at the
membrane.
Collapsin Response Mediator Protein 2
(CRMP2)
Collapsin response mediator protein 2 (CRMP2) is a protein
initially identiﬁed to be important for axonal outgrowth (Inagaki
et al., 2001). It is now known to be important for modulating
ion channel traﬃcking (Bretin et al., 2006; Chi et al., 2009).
CRMP2 is the secondary target of the anti-epileptic drug
lacosamide (Errington et al., 2006, 2008) and can directly bind
to Navs (Wang et al., 2010), modulating the channel’s slow
inactivation. In a recent study carried out in both HEK293
cells and sensory neurons, it was demonstrated that CRMP2
can be SUMOylated, which aﬀects Nav1.7 traﬃcking (Dustrude
et al., 2013). Whether SUMOylation of CRMP2 plays a role in
pathological pain via the alteration of Nav1.7 traﬃcking remains
to be investigated.
There are many other well described proteins, i.e., contactin
(Ranscht, 1988; Kazarinova-Noyes et al., 2001), ankyrin
(Malhotra et al., 2000), spectrin (Bennett and Baines, 2001),
dystrophin, and syntrophin (Gee et al., 1998; Abriel and Kass,
2005) among others (Shao et al., 2009), that interact with Navs
and modulate their function and cell surface expression. Kinases
are themselves substrates for PTMs that can modify their
function in important ways. All of these proteins are subject
to PTMs, which may impact the control of Nav function and
expression in peripheral chronic pain syndromes.
PTMs MODULATE Nav TRANSCRIPTION
In studies carried out in adrenal chromaﬃn cells, which express
relatively high levels of Nav1.7 (Klugbauer et al., 1995; Toledo-
Aral et al., 1995, 1997; Goldin, 2001; Wada et al., 2004, 2008),
a role for PTMs in controlling Nav transcription was proposed.
ERK kinases were shown to positively regulate Nav1.7 expression
at the membrane by modulating their mRNA stability (Yanagita
et al., 2003). Conversely, PKCε kinase activation destabilized
Nav1.7 mRNA, contributing to Nav1.7 negative regulation of the
steady-state levels at the plasmamembrane (Yanagita et al., 1996).
Whether similar mechanisms occur in sensory neurons has not
been reported.
DISCUSSION
Navs expression and function are dysregulated in peripheral
inﬂammatory pain, nerve injury induced neuropathic pain,
metabolic, infectious, toxic or inherited painful neuropathies.
Peripheral mechanisms for initiation and maintenance of pain
is partially due to the release of inﬂammatory molecules that
trigger diﬀerent signaling cascades and leads to the activation of
enzymes with diverse functions. In turn, these enzymes will post-
translationally modify Nav function and expression, ultimately
impacting nociceptive neuronal hyperexcitability and pain. Most
knowledge of such mechanisms comes from the kinase ﬁeld, but
since Navs are large proteins composed of over 2000 amino acids,
they possess a plethora of domains that could be subject to PTMs.
It is likely that PTM’s contribution to chronic pain syndromes are
still under-estimated and should be further investigated. In this
review, we not only discussed proven Nav PTMs implications in
pathological pain but also other potential relevant PTMs, which
will eventually open new avenues for a deeper understanding of
chronic pain syndromes. Together with the development of more
eﬃcient and speciﬁc pharmacological agonists and antagonists
targeting PTM eﬀectors, new genome engineering tools will
facilitate the generation of knock-in mice withmutations on PTM
sites or on the PTM eﬀectors themselves. This will hopefully help
conﬁrm and identify new pathways that regulate Nav function
and expression.
The pharmaceutical industry is attempting to develop highly
selective drugs that block Nav1.7, Nav1.8, or Nav1.9, but with
unfortunately little progress. This is partially due to the fact that
Navs are well-conserved proteins, and non-speciﬁc blockers are
bound to have many dramatic side eﬀects. Rather than targeting
and blocking the sodium channels themselves, regulating the
function or expression of sodium channels, which may havemore
subtle eﬀects on excitability, might prove to be an interesting
alternative to treat chronic pain. From this perspective, more
eﬀort should be focused on targeting PTM pathways, as
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exempliﬁed by the anti-TNF-α drug, which is promising and
still in expansion (Leung and Cahill, 2010). Pharmacological
targeting of the MAPK pathway has already been shown to
have an analgesic eﬀect (Tong et al., 2012), and many other
kinases are currently in pre-clinical or clinical studies (Ji et al.,
2007). Other promising avenues include the use of scavengers
of methylglyoxal (Bierhaus et al., 2012) or the use of gene
therapy to restore Nedd4-2 ubiquitylating function, which have
proven to be eﬃcient in relieving pain in animal models of
chronic pain. Altogether, it is important to further characterize
the known PTM eﬀects on Navs and to identify new PTMs
in order to gain insight into the development of pathological
pain.
FUNDING
The authors are supported by grants from the Swiss National
Science Foundation (Early-postdoc.mobility P2LAP3_151557 to
C.J.L. 310030_159615/1 to ID and 310030B- 135693 to HA).
ACKNOWLEDGMENTS
We thank Dr. E. Buttermore and Dr. A. Felley for their comments
on the manuscript of this chapter. We thank Desi Ivanova for her
help with Figure 1. Images fromMotifolio drawing toolkit (www.
motifolio.com) were used in Figure 1 preparation.
REFERENCES
Abdulla, F. A., and Smith, P. A. (2002). Changes in Na(+) channel
currents of rat dorsal root ganglion neurons following axotomy and
axotomy-induced autotomy. J. Neurophysiol. 88, 2518–2529. doi: 10.1152/jn.
00913.2001
Abrahamsen, B., Zhao, J., Asante, C. O., Cendan, C. M., Marsh, S., Martinez-
Barbera, J. P., et al. (2008). The cell and molecular basis of mechanical, cold,
and inﬂammatory pain. Science 321, 702–705.
Abriel, H., Kamynina, E., Horisberger, J. D., and Staub, O. (2000). Regulation of
the cardiac voltage-gated Na+ channel (H1) by the ubiquitin-protein ligase
NEDD4. FEBS Lett. 466, 377–380.
Abriel, H., and Kass, R. S. (2005). Regulation of the voltage-gated cardiac sodium
channel Nav1.5 by interacting proteins. Trends Cardiovasc. Med. 15, 35–40. doi:
10.1016/j.tcm.2005.01.001
Abriel, H., Loﬃng, J., Rebhun, J. F., Pratt, J. H., Schild, L., Horisberger, J. D., et al.
(1999). Defective regulation of the epithelial Na+ channel byNEDD4 in Liddle’s
syndrome. J. Clin. Invest. 103, 667–673. doi: 10.1172/JCI5713
Abriel, H., and Staub, O. (2005). Ubiquitylation of ion channels. Physiology
(Bethesda) 20, 398–407. doi: 10.1152/physiol.00033.2005
Akopian, A., Sivilotti, L., and Wood, J. (1996). A tetrodotoxin-resistant voltage-
gated sodium channel expressed by sensory neurons. Nature 379, 257–262.
Akopian, A. N., Souslova, V., England, S., Okuse, K., Ogata, N., Ure, J., et al. (1999).
The tetrodotoxin-resistant sodium channel SNS has a specialized function in
pain pathways. Nat. Neurosci. 2, 541–548.
Akopian, A. N., Souslova, V., Sivilotti, L., and Wood, J. N. (1997). Structure and
distribution of a broadly expressed atypical sodium channel. FEBS Lett. 400,
183–187. doi: 10.1016/s0014-5793(96)01389-0
Aley, K. O., and Levine, J. D. (1999). Role of protein kinase A in the maintenance
of inﬂammatory pain. J. Neurosci. 19, 2181–2186.
Aley, K. O., Messing, R. O., Mochly-Rosen, D., and Levine, J. D. (2000). Chronic
hypersensitivity for inﬂammatory nociceptor sensitization mediated by the ε
isozyme of protein kinase C. J. Neurosci. 20, 4680–4685.
Amaya, F., Wang, H., Costigan, M., Allchorne, A., Hatcher, J., Egerton, J., et al.
(2006). The voltage-gated sodium channel Na(v)1.9 is an eﬀector of peripheral
inﬂammatory pain hypersensitivity. J. Neurosci. 26, 12852–12860.
Arévalo, J. C.,Waite, J., Rajagopal, R., Beyna,M., Chen, Z. Y., Lee, F. S., et al. (2006).
Cell survival through trk neurotrophin receptors is diﬀerentially regulated by
ubiquitination. Neuron 50, 549–559. doi: 10.1016/j.neuron.2006.03.044
Bair, M. J., Robinson, R. L., Katon, W., and Kroenke, K. (2003). Depression and
pain comorbidity: a literature review. Arch. Intern. Med. 163, 2433–2445. doi:
10.1001/archinte.163.20.2433
Basbaum, A., Bautista, D., Scherrer, G., and Julius, D. (2009). Cellular and
molecular mechanisms of pain. Cell 139, 267–284.
Battaini, F. (2001). Protein kinase C isoforms as therapeutic targets in nervous
system disease states. Pharmacol. Res. 44, 353–361.
Bendahhou, S., Cummins, T. R., Potts, J. F., Tong, J., and Agnew, W. S.
(1995). Serine-1321-independent regulation of the mu 1 adult skeletal
muscle Na+ channel by protein kinase C. Proc. Natl. Acad. Sci. U.S.A. 92,
12003–12007.
Beneski, D. A., and Catterall, W. A. (1980). Covalent labeling of protein
components of the sodium channel with a photoactivable derivative of scorpion
toxin. Proc. Natl. Acad. Sci. U.S.A. 77, 639–643.
Ben-Johny, M., Yang, P. S., Niu, J., Yang, W., Joshi-Mukherjee, R., and Yue, D. T.
(2014). Conservation of Ca2+/Calmodulin regulation across Na and Ca2+
channels. Cell 157, 1657–1670.
Bennett, E., Urcan, M. S., Tinkle, S. S., Koszowski, A. G., and Levinson, S. R. (1997).
Contribution of sialic acid to the voltage dependence of sodium channel gating.
J. Gen. Physiol. 109, 327–343. doi: 10.1085/jgp.109.3.327
Bennett, V., and Baines, A. J. (2001). Spectrin and ankyrin-based pathways:
metazoan inventions for integrating cells into tissues. Physiol. Rev. 81, 1353–
1392.
Berta, T., Poirot, O., Pertin, M., Ji, R., Kellenberger, S., and Decosterd, I. (2008).
Transcriptional and functional proﬁles of voltage-gated Na(+) channels in
injured and non-injured DRG neurons in the SNI model of neuropathic pain.
Mol. Cell. Neurosci. 37, 196–208.
Bierhaus, A., Fleming, T., Stoyanov, S., Leﬄer, A., Babes, A., Neacsu, C., et al.
(2012). Methylglyoxal modiﬁcation of Nav1.8 facilitates nociceptive neuron
ﬁring and causes hyperalgesia in diabetic neuropathy. Nat. Med. 18, 926–933.
doi: 10.1038/nm.2750
Bierhaus, A., and Nawroth, P. P. (2009). Multiple levels of regulation
determine the role of the receptor for AGE (RAGE) as common soil
in inﬂammation, immune responses and diabetes mellitus and its
complications. Diabetologia 52, 2251–2263. doi: 10.1007/s00125-009-1
458-9
Bird, E., Christmas, C., Loescher, A., Smith, K., Robinson, P., Black, J., et al. (2013).
Correlation of Nav1.8 and Nav1.9 sodium channel expression with neuropathic
pain in human subjects with lingual nerve neuromas.Mol. Pain 9:52.
Bird, E. V., Robinson, P. P., and Boissonade, F. M. (2007). Nav1.7 sodium channel
expression in human lingual nerve neuromas. Arch. Oral Biol. 52, 494–502. doi:
10.1016/j.archoralbio.2006.11.011
Biswas, S., Deschênes, I., Disilvestre, D., Tian, Y., Halperin, V. L., and Tomaselli,
G. F. (2008). Calmodulin regulation of NaV1.4 current: role of binding to the
carboxyl terminus. J. Gen. Physiol. 131, 197–209. doi: 10.1085/jgp.200709863
Black, J. A., Dib-Hajj, S., Mcnabola, K., Jeste, S., Rizzo, M., Kocsis, J., et al.
(1996). Spinal sensory neurons express multiple sodium channel alpha-subunit
mRNAs. Brain Res. Mol. Brain Res. 43, 117–131.
Black, J. A., Liu, S., Tanaka, M., Cummins, T. R., and Waxman, S. G. (2004).
Changes in the expression of tetrodotoxin-sensitive sodium channels within
dorsal root ganglia neurons in inﬂammatory pain. Pain 108, 237–247. doi:
10.1016/j.pain.2003.12.035
Black, J. A., Nikolajsen, L., Kroner, K., Jensen, T., and Waxman, S. (2008). Multiple
sodium channel isoforms and mitogen-activated protein kinases are present in
painful human neuromas. Ann. Neurol. 64, 644–653.
Bongiorno, D., Schuetz, F., Poronnik, P., and Adams, D. J. (2011). Regulation of
voltage-gated ion channels in excitable cells by the ubiquitin ligases Nedd4 and
NEDD4-2. Channels (Austin) 5, 79–88.
Bouhassira, D., Lanteri-Minet, M., Attal, N., Laurent, B., and Touboul, C. (2008).
Prevalence of chronic pain with neuropathic characteristics in the general
population. Pain 136, 380–387. doi: 10.1016/j.pain.2007.08.013
Frontiers in Pharmacology | www.frontiersin.org 12 November 2015 | Volume 6 | Article 263
Laedermann et al. Pain and post-translational modifications of sodium channels
Bretin, S., Rogemond, V., Marin, P., Maus, M., Torrens, Y., Honnorat, J., et al.
(2006). Calpain product of WT-CRMP2 reduces the amount of surface NR2B
NMDA receptor subunit. J. Neurochem. 98, 1252–1265. doi: 10.1111/j.1471-
4159.2006.03969.x
Brouwer, B. A., Merkies, I. S. J., Gerrits,M.M.,Waxman, S. G., Hoeijmakers, J. G. J.,
and Faber, C. G. (2014). Painful neuropathies: the emerging role of sodium
channelopathies. J. Peripher. Nerv. Syst. 19, 53–65. doi: 10.1111/jns5.12071
Brower, V. (2000). New paths to pain relief. Nat. Biotech. 18, 387–391.
Brüggemann, I., Schulz, S., Wiborny, D., and Höllt, V. (2000). Colocalization
of the μ-opioid receptor and calcium/calmodulin-dependent kinase II in
distinct pain-processing brain regions1. Mol. Brain Res. 85, 239–250. doi:
10.1016/S0169-328X(00)00265-5
Cachemaille, M., Laedermann, C. J., Pertin, M., Abriel, H., Gosselin, R. D.,
and Decosterd, I. (2012). Neuronal expression of the ubiquitin ligase
NEDD4-2 in rat dorsal root ganglia: modulation in the spared nerve
injury model of neuropathic pain. Neuroscience 227, 370–380. doi: 10.1016/j.
neuroscience.2012.09.044
Campbell, J., and Meyer, R. (2006). Mechanisms of neuropathic pain. Neuron 52,
77–92.
Cang, C.-L., Zhang, H., Zhang, Y.-Q., and Zhao, Z.-Q. (2009). PKCepsilon-
dependent potentiation of TTX-resistant Nav1.8 current by neurokinin-1
receptor activation in rat dorsal root ganglion neurons.Mol. Pain 5:33.
Cantrell, A. R., Ma, J. Y., Scheuer, T., and Catterall, W. A. (1996). Muscarinic
modulation of sodium current by activation of protein kinase C in
rat hippocampal neurons. Neuron 16, 1019–1026. doi: 10.1016/S0896-
6273(00)80125-7
Cantrell, A. R., Smith, R. D., Goldin, A. L., Scheuer, T., and Catterall, W. A.
(1997). Dopaminergic modulation of sodium current in hippocampal neurons
via camp-dependent phosphorylation of speciﬁc sites in the sodium channel α
subunit. J. Neurosci. 17, 7330–7338.
Casals-Diaz, L., Casas, C., and Navarro, X. (2015). Changes of voltage-gated
sodium channels in sensory nerve regeneration and neuropathic pain models.
Restor. Neurol. Neurosci. 33, 321–324. doi: 10.3233/RNN-140444
Catterall, W., Goldin, A., and Waxman, S. (2005). International union of
pharmacology. XLVII. Nomenclature and structure-function relationships of
voltage-gated sodium channels. Pharmacol. Rev. 57, 397–409.
Catterall, W. A. (1992). Cellular and molecular biology of voltage-gated sodium
channels. Physiol. Rev. 72, S15–S48.
Cesare, P., Dekker, L. V., Sardini, A., Parker, P. J., and Mcnaughton, P. A. (1999).
Speciﬁc Involvement of PKC-ε in sensitization of the neuronal response to
painful Heat. Neuron. 23, 617–624. doi: 10.1016/S0896-6273(00)80813-2
Cesare, P., and McNaughton, P. (1996). A novel heat-activated current in
nociceptive neurons and its sensitization by bradykinin. Proc. Natl. Acad. Sci.
U.S.A. 93, 15435–15439.
Chahine, M., Ziane, R., Vijayaragavan, K., and Okamura, Y. (2005). Regulation
of Na v channels in sensory neurons. Trends Pharmacol. Sci. 26, 496–502. doi:
10.1016/j.tips.2005.08.002
Chatelier, A., Dahllund, L., Eriksson, A., Krupp, J., and Chahine, M. (2008).
Biophysical properties of human Nav1.7 splice variants and their regulation by
protein kinase A. J. Neurophysiol. 99, 2241–2250.
Chattopadhyay, M., Mata, M., and Fink, D. J. (2008). Continuous δ-opioid
receptor activation reduces neuronal voltage-gated sodium channel (NaV1.7)
levels through activation of protein kinase C in painful diabetic neuropathy.
J. Neurosci. 28, 6652–6658. doi: 10.1523/jneurosci.5530-07.2008
Chen, Y., Luo, F., Yang, C., Kirkmire, C. M., and Wang, Z. J. (2009).
Acute inhibition of Ca2+/Calmodulin-dependent protein kinase II reverses
experimental neuropathic pain in mice. J. Pharmacol. Exp. Ther. 330, 650–659.
doi: 10.1124/jpet.109.152165
Chen, Y., Yu, F. H., Sharp, E. M., Beacham, D., Scheuer, T., and Catterall,
W. A. (2008). Functional properties and diﬀerential neuromodulation of
Na(v)1.6 Channels. Mol. Cell. Neurosci. 38, 607–615. doi: 10.1016/j.mcn.2008.
05.009
Cheng, X., Dib-Hajj, S., Tyrrell, L., and Waxman, S. (2008). Mutation I136V alters
electrophysiological properties of the NaV1.7 channel in a family with onset of
erythromelalgia in the second decade.Mol. Pain 4:1.
Chi, X. X., Schmutzler, B. S., Brittain, J. M., Wang, Y., Hingtgen, C. M., Nicol,
G. D., et al. (2009). Regulation of N-type voltage-gated calcium channels
(Cav2.2) and transmitter release by collapsin response mediator protein-2
(CRMP-2) in sensory neurons. J. Cell Sci. 122, 4351–4362. doi: 10.1242/jcs.05
3280
Ciechanover, A. (2005). Proteolysis: from the lysosome to ubiquitin and the
proteasome. Nat. Rev. Mol. Cell Biol. 6, 79–87. doi: 10.1038/nrm1552
Coggeshall, R. E., Tate, S., and Carlton, S. M. (2004). Diﬀerential expression
of tetrodotoxin-resistant sodium channels Nav1.8 and Nav1.9 in normal and
inﬂamed rats. Neurosci. Lett. 355, 45–48. doi: 10.1016/j.neulet.2003.10.023
Cohen, S. A., and Barchi, R. L. (1993). Voltage-dependent sodium channels. Int.
Rev. Cytol. 137C, 55–103.
Costa, M. R. C., and Catterall, W. A. (1984a). Cyclic AMP-dependent
phosphorylation of the α subunit of the sodium channel in synaptic nerve
ending particles. J. Biol. Chem. 259, 8210–8218.
Costa, M. R. C., and Catterall, W. A. (1984b). Phosphorylation of the α subunit of
the sodium channel by protein kinase C. Cell Mol. Neurobiol. 4, 291–297. doi:
10.1007/BF00733592
Coward, K., Aitken, A., Powell, A., Plumpton, C., Birch, R., Tate, S., et al. (2001a).
Plasticity of TTX-sensitive sodium channels PN1 and brain III in injured
human nerves. NeuroReport 12, 495–500.
Coward, K., Jowett, A., Plumpton, C., Powell, A., Birch, R., Tate, S., et al. (2001b).
Sodium channel beta 1 and beta 2 subunits parallel SNS/PN3 alpha-subunit
changes in injured human sensory neurons. NeuroReport 12, 483–488. doi:
10.1097/00001756-200103050-00012
Cox, J. J., Reimann, F., Nicholas, A. K., Thornton, G., Roberts, E., Springell, K., et al.
(2006). An SCN9A channelopathy causes congenital inability to experience
pain. Nature 444, 894–898. doi: 10.1038/nature05413
Cronin, N. B., O’Reilly, A., Duclohier, H., and Wallace, B. A. (2004). Eﬀects
of Deglycosylation of sodium channels on their structure and function.
Biochemistry 44, 441–449. doi: 10.1021/bi048741q
Cummins, T. R., Aglieco, F., Renganathan, M., Herzog, R. I., Dib-Hajj, S. D.,
and Waxman, S. G. (2001). Nav1.3 sodium channels: rapid repriming and
slow closed-state inactivation display quantitative diﬀerences after expression
in a mammalian cell line and in spinal sensory neurons. J. Neurosci. 21,
5952–5961.
Cummins, T., Dib-Hajj, S., andWaxman, S. (2004). Electrophysiological properties
of mutant Nav1.7 sodium channels in a painful inherited neuropathy.
J. Neurosci. 24, 8232–8236.
Cummins, T. R., and Waxman, S. G. (1997). Downregulation of tetrodotoxin-
resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-
sensitive sodium current in small spinal sensory neurons after nerve injury.
J. Neurosci. 17, 3503–3514.
Cusdin, F. S., Clare, J. J., and Jackson, A. P. (2008). Traﬃcking and
cellular distribution of voltage-gated sodium channels. Traﬃc 9, 17–26. doi:
10.1111/j.1600-0854.2007.00673.x
Daemen, M., Kurvers, H., Kitslaar, P., Slaaf, D., Bullens, P., and Wildenberg, F.
(1998). Neurogenic inﬂammation in an animal model of neuropathic pain.
Neurol. Res. 20, 41–45.
Dascal, N., and Lotan, I. (1991). Activation of protein kinase C alters voltage
dependence of a Na+ channel. Neuron 6, 165–175. doi: 10.1016/0896-
6273(91)90131-I
Decosterd, I., Ji, R., Abdi, S., Tate, S., and Woolf, C. (2002). The pattern of
expression of the voltage-gated sodium channels Na(v)1.8 and Na(v)1.9 does
not change in uninjured primary sensory neurons in experimental neuropathic
pain models. Pain 96, 269–277.
Deribe, Y. L., Pawson, T., and Dikic, I. (2010). Post-translational modiﬁcations in
signal integration. Nat. Struct. Mol. Biol. 17, 666–672.
Deschênes, I., Neyroud, N., Disilvestre, D., Marbán, E., Yue, D. T., and
Tomaselli, G. F. (2002). Isoform-speciﬁc modulation of voltage-gated Na+
channels by calmodulin. Circ. Res. 90, e49–e57. doi: 10.1161/01.res.0000012502.
92751.e6
Deval, E., Gasull, X., Noël, J., Salinas, M., Baron, A., Diochot, S., et al. (2010).
Acid-Sensing ion channels (ASICs): pharmacology and implication in pain.
Pharmacol. Ther. 128, 549–558. doi: 10.1016/j.pharmthera.2010.08.006
Dib-Hajj, S. D., Binshtok, A. M., Cummins, T. R., Jarvis, M. F., Samad, T., and
Zimmermann, K. (2009). Voltage-gated sodium channels in pain states: role
in pathophysiology and targets for treatment. Brain Res. Rev. 60, 65–83. doi:
10.1016/j.brainresrev.2008.12.005
Dib-Hajj, S. D., Cummins, T., Black, J., and Waxman, S. (2010). Sodium channels
in normal and pathological pain. Annu. Rev. Neurosci. 33, 325–347.
Frontiers in Pharmacology | www.frontiersin.org 13 November 2015 | Volume 6 | Article 263
Laedermann et al. Pain and post-translational modifications of sodium channels
Dib-Hajj, S. D., Rush, A. M., Cummins, T. R., Hisama, F. M., Novella, S., Tyrrell, L.,
et al. (2005). Gain-of-function mutation in NaV1.7 in familial erythromelalgia
induces bursting of sensory neurons. Brain 128, 1847–1854.
Dib-Hajj, S. D., Tyrrell, L., Black, J., and Waxman, S. (1998). NaN, a novel voltage-
gated Na channel, is expressed preferentially in peripheral sensory neurons and
down-regulated after axotomy. Proc. Natl. Acad. Sci. U.S.A. 95, 8963–8968.
Dib-Hajj, S. D., Yang, Y., Black, J., and Waxman, S. (2013). The Na(V)1.7 sodium
channel: from molecule to man. Nat. Rev. Neurosci. 14, 49–62.
Dietrich, P. S., Mcgivern, J. G., Delgado, S. G., Koch, B. D., Eglen, R. M., Hunter,
J. C., et al. (1998). Functional analysis of a voltage-gated sodium channel and
its splice variant from rat dorsal root ganglia. J. Neurochem. 70, 2262–2272. doi:
10.1046/j.1471-4159.1998.70062262.x
Dina, O. A., Barletta, J., Chen, X., Mutero, A., Martin, A., Messing, R. O., et al.
(2000). Key role for the epsilon isoform of protein kinase C in painful alcoholic
neuropathy in the rat. J. Neurosci. 20, 8614–8619.
Dina, O. A., Chen, X., Reichling, D., and Levine, J. D. (2001). Role of
protein kinase Cε and protein kinase A in a model of paclitaxel-induced
painful peripheral neuropathy in the rat. Neuroscience 108, 507–515. doi:
10.1016/S0306-4522(01)00425-0
Djouhri, L., Koutsikou, S., Fang, X., Mcmullan, S., and Lawson, S. N. (2006).
Spontaneous pain, both neuropathic and inﬂammatory, is related to frequency
of spontaneous ﬁring in intact C-ﬁber nociceptors. J. Neurosci. 26, 1281–1292.
doi: 10.1523/JNEUROSCI.3388-05.2006
Dogrul, A., Gul, H., Yesilyurt, O., Ulas, U., and Yildiz, O. (2011). Systemic and
spinal administration of etanercept, a tumor necrosis factor alpha inhibitor,
blocks tactile allodynia in diabetic mice. Acta Diabetol. 48, 135–142. doi:
10.1007/s00592-010-0237-x
Dong, X. W., Goregoaker, S., Engler, H., Zhou, X., Mark, L., Crona, J., et al. (2007).
Small interfering RNA-mediated selective knockdown of NaV1.8 tetrodotoxin-
resistant sodium channel reverses mechanical allodynia in neuropathic
rats. Neuroscience 146, 812–821. doi: 10.1016/j.neuroscience.2007.0
1.054
Duan, B., Liu, D.-S., Huang, Y., Zeng, W.-Z., Wang, X., Yu, H., et al. (2012). PI3-
kinase/Akt pathway-regulated membrane insertion of acid-sensing ion channel
1a underlies BDNF-induced pain hypersensitivity. J. Neurosci. 32, 6351–6363.
doi: 10.1523/jneurosci.4479-11.2012
Dubin, A. E., and Patapoutian, A. (2010). Nociceptors: the sensors of the pain
pathway. J. Clin. Invest. 120, 3760–3772. doi: 10.1172/jci42843
Dustrude, E. T., Wilson, S. M., Ju, W., Xiao, Y., and Khanna, R. (2013). CRMP2
protein SUMOylationmodulates NaV1.7 channel traﬃcking. J. Biol. Chem. 288,
24316–24331. doi: 10.1074/jbc.M113.474924
Edinger, R. S., Lebowitz, J., Li, H., Alzamora, R., Wang, H., Johnson, J. P., et al.
(2009). Functional regulation of the epithelial Na+ channel by IκB kinase-β
occurs via phosphorylation of the ubiquitin ligase Nedd4-2. J. Biol. Chem. 284,
150–157. doi: 10.1074/jbc.M807358200
Ednie, A. R., and Bennett, E. S. (2011). “Modulation of voltage-gated ion channels
by sialylation,” in Comprehensive Physiology, ed. D. M. Pollock (New York, NY:
JohnWiley & Sons, Inc.).
England, S., Bevan, S., and Docherty, R. J. (1996). PGE2 modulates the
tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion
neurones via the cyclic AMP-protein kinase A cascade. J. Physiol. 495, 429–440.
doi: 10.1113/jphysiol.1996.sp021604
Errington, A. C., Coyne, L., Stöhr, T., Selve, N., and Lees, G. (2006).
Seeking a mechanism of action for the novel anticonvulsant lacosamide.
Neuropharmacology 50, 1016–1029. doi: 10.1016/j.neuropharm.2006.02.002
Errington, A. C., Stöhr, T., Heers, C., and Lees, G. (2008). The investigational
anticonvulsant lacosamide selectively enhances slow inactivation of
voltage-gated sodium channels. Mol. Pharmacol. 73, 157–169. doi:
10.1124/mol.107.039867
Faber, C. G., Hoeijmakers, J. G., Ahn, H. S., Cheng, X., Han, C., Choi, J. S.,
et al. (2012a). Gain of function Nanu1.7 mutations in idiopathic small ﬁber
neuropathy. Ann. Neurol. 71, 26–39. doi: 10.1002/ana.22485
Faber, C. G., Lauria, G., Merkies, I. S., Cheng, X., Han, C., Ahn, H. S., et al. (2012b).
Gain-of-function Nav1.8 mutations in painful neuropathy. Proc. Natl. Acad. Sci.
U.S.A. 109, 19444–19449. doi: 10.1073/pnas.1216080109
Fahmi, A. I., Patel, M., Stevens, E. B., Fowden, A. L., John, J. E., Lee, K., et al.
(2001). The sodium channel -subunit SCN3b modulates the kinetics of SCN5a
and is expressed heterogeneously in sheep heart. J. Physiol. 537, 693–700. doi:
10.1113/jphysiol.2001.012691
Ferrari, L. F., Bogen, O., and Levine, J. D. (2013). Role of nociceptor αCaMKII
in transition from acute to chronic pain (Hyperalgesic Priming) in male and
female rats. J. Neurosci. 33, 11002–11011. doi: 10.1523/jneurosci.1785-13.2013
Ferreira, J., Trichês, K. M., Medeiros, R., Cabrini, D. A., Mori, M. A. S., Pesquero,
J. B., et al. (2008). The role of kinin B1 receptors in the nociception produced
by peripheral protein kinase C activation in mice. Neuropharmacology 54,
597–604. doi: 10.1016/j.neuropharm.2007.11.008
Ferreira, J., Trichês, K. M., Medeiros, R., and Calixto, J. B. (2005). Mechanisms
involved in the nociception produced by peripheral protein kinase C activation
in mice. Pain 117, 171–181. doi: 10.1016/j.pain.2005.06.001
Fertleman, C. R., Baker, M. D., Parker, K. A., Moﬀatt, S., Elmslie, F. V.,
Abrahamsen, B., et al. (2006). SCN9A mutations in paroxysmal extreme pain
disorder: allelic variants underlie distinct channel defects and phenotypes.
Neuron 52, 767–774. doi: 10.1016/j.neuron.2006.10.006
Firsov, D., Schild, L., Gautschi, I., MéRillat, A. M., Schneeberger, E., and Rossier,
B. C. (1996). Cell surface expression of the epithelial Na channel and a mutant
causing Liddle syndrome: a quantitative approach. Proc. Natl. Acad. Sci. U.S.A.
93, 15370–15375.
Fitzgerald, E. M., Okuse, K., Wood, J. N., Dolphin, A. C., and Moss, S. J. (1999).
cAMP-dependent phosphorylation of the tetrodotoxin-resistant voltage-
dependent sodium channel SNS. J. Physiol. 516, 433–446. doi: 10.1111/j.1469-
7793.1999.0433v.x
Fjell, J., Cummins, T. R., Dib-Hajj, S. D., Fried, K., Black, J. A., and Waxman, S. G.
(1999). Diﬀerential role of GDNF and NGF in the maintenance of two TTX-
resistant sodium channels in adult DRG neurons. Mol. Brain Res. 67, 267–282.
doi: 10.1016/S0169-328X(99)00070-4
Fotia, A. B., Dinudom, A., Shearwin, K. E., Koch, J.-P., Korbmacher, C., Cook,
D. I., et al. (2002). The role of individual NEDD4-2 (KIAA0439) WW domains
in binding and regulating epithelial sodium channels. FASEB J. 17, 70–72. doi:
10.1096/fj.02-0497fje
Fotia, A. B., Ekberg, J., Adams, D. J., Cook, D. I., Poronnik, P., and Kumar, S.
(2004). Regulation of neuronal voltage-gated sodium channels by the ubiquitin-
protein ligases Nedd4 and NEDD4-2. J. Biol. Chem. 279, 28930–28935. doi:
10.1074/jbc.M402820200
Fukuoka, T., Kobayashi, K., Yamanaka, H., Obata, K., Dai, Y., and Noguchi, K.
(2008). Comparative study of the distribution of the alpha-subunits of
voltage-gated sodium channels in normal and axotomized rat dorsal root
ganglion neurons. J. Comp. Neurol. 510, 188–206. doi: 10.1002/cne.2
1786
Fukuoka, T., and Noguchi, K. (2011). Comparative study of voltage-gated
sodium channel alpha-subunits in non-overlapping four neuronal
populations in the rat dorsal root ganglion. Neurosci. Res. 70, 164–171.
doi: 10.1016/j.neures.2011.01.020
Galan, A., Laird, J. M. A., and Cervero, F. (2004). In vivo recruitment by painful
stimuli of AMPA receptor subunits to the plasma membrane of spinal cord
neurons. Pain 112, 315–323. doi: 10.1016/j.pain.2004.09.011
Gasser, A., Cheng, X., Gilmore, E. S., Tyrrell, L., Waxman, S. G., and Dib-
Hajj, S. D. (2010). Two Nedd4-binding motifs underlie modulation of
sodium channel Nav1.6 by p38 MAPK. J. Biol. Chem. 285, 26149–26161. doi:
10.1074/jbc.M109.098681
Gaudet, A., Popovich, P., and Ramer, M. (2011). Wallerian degeneration:
gaining perspective on inﬂammatory events after peripheral nerve injury.
J. Neuroinﬂamm. 8:110.
Gee, S., Madhavan, R., Levinson, S., Caldwell, J., Sealock, R., and Froehner, S.
(1998). Interaction of muscle and brain sodium channels with multiple
members of the syntrophin family of dystrophin-associated proteins.
J. Neurosci. 18, 128–137.
Gershon, E., Weigl, L., Lotan, I., Schreibmayer, W., and Dascal, N. (1992).
Protein kinase A reduces voltage-dependent Na+ current in Xenopus oocytes.
J. Neurosci. 12, 3743–3752.
Gold, M., Levine, J., and Correa, A. (1998). Modulation of TTX-R I Na by PKC
and PKA and their role in PGE2-induced sensitization of rat sensory neurons
in vitro. J. Neurosci. 18, 10345–10355.
Gold, M. S., Reichling, D. B., Shuster, M. J., and Levine, J. D. (1996). Hyperalgesic
agents increase a tetrodotoxin-resistant Na+ current in nociceptors. Proc. Natl.
Acad. Sci. U.S.A. 93, 1108–1112.
Gold, M. S., Weinreich, D., Kim, C. S., Wang, R., Treanor, J., Porreca, F., et al.
(2003). Redistribution of NaV1.8 in uninjured axons enables neuropathic pain.
J. Neurosci. 23, 158–166.
Frontiers in Pharmacology | www.frontiersin.org 14 November 2015 | Volume 6 | Article 263
Laedermann et al. Pain and post-translational modifications of sodium channels
Goldin, A. L. (2001). Resurgence of sodium channel research. Annu. Rev. Physiol.
63, 871–894. doi: 10.1146/annurev.physiol.63.1.871
Gould, H. J., Gould, T. N., England, J. D., Paul, D., Liu, Z. P., and Levinson,
S. R. (2000). A possible role for nerve growth factor in the augmentation
of sodium channels in models of chronic pain. Brain Res. 854, 19–29. doi:
10.1016/s0006-8993(99)02216-7
Gudes, S., Barkai, O., Caspi, Y., Katz, B., Lev, S., and Binshtok, A. M. (2015).
The role of slow and persistent TTX-resistant sodium currents in acute tumor
necrosis factor-α-mediated increase in nociceptors excitability. J. Neurophysiol.
113, 601–619. doi: 10.1152/jn.00652.2014
Han, C., Vasylyev, D., Macala, L. J., Gerrits, M. M., Hoeijmakers, J. G. J., Bekelaar,
K. J., et al. (2014). The G1662S NaV1.8 mutation in small ﬁbre neuropathy:
impaired inactivation underlying DRG neuron hyperexcitability. J. Neurol.
Neurosurg. Psychiatry 85, 499–505. doi: 10.1136/jnnp-2013-306095
Heikamp, E. B., Patel, C. H., Collins, S., Waickman, A., Oh, M.-H., Sun, I.-H.,
et al. (2014). The AGC kinase SGK1 regulates TH1 and TH2 diﬀerentiation
downstream of the mTORC2 complex. Nat. Immunol. 15, 457–464. doi:
10.1038/ni.2867
Henry, P. C., Kanelis, V., O’Brien, M. C., Kim, B., Gautschi, I., Forman-
Kay, J., et al. (2003). Aﬃnity and speciﬁcity of interactions between Nedd4
isoforms and the epithelial Na+ channel. J. Biol. Chem. 278, 20019–20028. doi:
10.1074/jbc.M211153200
Herzog, R. I., Cummins, T. R., and Waxman, S. G. (2001). Persistent TTX-
resistant Na+ current aﬀects resting potential and response to depolarization
in simulated spinal sensory neurons. J. Neurophysiol. 86, 1351–1364.
Herzog, R. I., Liu, C., Waxman, S. G., and Cummins, T. R. (2003). Calmodulin
binds to the C terminus of sodium channels Nav1.4 and Nav1.6 and
diﬀerentially modulates their functional properties. J. Neurosci. 23, 8261–8270.
Hirade, M., Yasuda, H., Omatsu-Kanbe, M., Kikkawa, R., and Kitasato, H.
(1999). Tetrodotoxin-resistant sodium channels of dorsal root ganglion
neurons are readily activated in diabetic rats. Neuroscience 90,
933–939.
Hiruma, H., Maruyama, H., Katakura, T., Simada, Z. I. B., Nishida, S., Hoka, S.,
et al. (1999). Axonal transport is inhibited by a protein kinase C inhibitor in
cultured isolated mouse dorsal root ganglion cells. Brain Res. 826, 135–138. doi:
10.1016/S0006-8993(99)01249-4
Ho, C., and O’Leary, M. E. (2011). Single-cell analysis of sodium channel
expression in dorsal root ganglion neurons. Mol. Cell. Neurosci. 46, 159–166.
doi: 10.1016/j.mcn.2010.08.017
Hockley, J. R. F., Boundouki, G., Cibert-Goton,V.,Mcguire, C., Yip, P. K., Chan, C.,
et al. (2014). Multiple roles for Na(V)1.9 in the activation of visceral aﬀerents by
noxious inﬂammatory, mechanical, and human disease–derived stimuli. Pain
155, 1962–1975. doi: 10.1016/j.pain.2014.06.015
Hoeijmakers, J. G. J., Faber, C. G., Merkies, I. S. J., and Waxman, S. G. (2015).
Painful peripheral neuropathy and sodium channel mutations. Neurosci. Lett.
596, 51–59. doi: 10.1016/j.neulet.2014.12.056
Hoeijmakers, J. G. J., Merkies, I. S. J., Gerrits, M. M., Waxman, S. G., and
Faber, C. G. (2012). Genetic aspects of sodium channelopathy in small ﬁber
neuropathy. Clin. Gen. 82, 351–358. doi: 10.1111/j.1399-0004.2012.01937.x
Huang, J., Han, C., Estacion, M., Vasylyev, D., Hoeijmakers, J. G. J., Gerrits, M. M.,
et al. (2014). Gain-of-function mutations in sodium channel NaV1.9 in painful
neuropathy. Brain. 137(Pt 6), 1627–1642. doi: 10.1093/brain/awu079
Hucho, T., and Levine, J. D. (2007). Signaling pathways in sensitization: toward a
nociceptor cell biology.Neuron 55, 365–376. doi: 10.1016/j.neuron.2007.07.008
Hudmon, A., Choi, J.-S., Tyrrell, L., Black, J. A., Rush, A. M., Waxman, S. G., et al.
(2008). Phosphorylation of sodium channel Nav1.8 by p38 mitogen-activated
protein kinase increases current density in dorsal root Ganglion Neurons.
J. Neurosci. 28, 3190–3201. doi: 10.1523/jneurosci.4403-07.2008
Hunter, T. (2009). Tyrosine phosphorylation: thirty years and counting. Curr.
Opin. Cell Biol. 21, 140–146. doi: 10.1016/j.ceb.2009.01.028
Ikeda, M., Yoshida, S., Kadoi, J., Nakano, Y., and Mastumoto, S. (2005). The
eﬀect of PKC activity on the TTX-R sodium currents from rat nodose ganglion
neurons. Life Sci. 78, 47–53. doi: 10.1016/j.lfs.2005.04.053
Inagaki, N., Chihara, K., Arimura, N., Menager, C., Kawano, Y., Matsuo, N.,
et al. (2001). CRMP-2 induces axons in cultured hippocampal neurons. Nat.
Neurosci. 4, 781–782.
Isom, L., De Jongh, K., Patton, D., Reber, B., Oﬀord, J., Charbonneau, H.,
et al. (1992). Primary structure and functional expression of the beta
1 subunit of the rat brain sodium channel. Science 256, 839–842. doi:
10.1126/science.256.5058.839
Isom, L. L., Ragsdale, D. S., De Jongh, K. S., Westenbroek, R. E., Reber, B. F. X.,
Scheuer, T., et al. (1995a). Structure and function of the β2 subunit of brain
sodium channels, a transmembrane glycoprotein with a CAM motif. Cell 83,
433–442. doi: 10.1016/0092-8674(95)90121-3
Isom, L. L., Scheuer, T., Brownstein, A. B., Ragsdale, D. S., Murphy, B. J., and
Catterall, W. A. (1995b). Functional co-expression of the beta 1 and type IIA
alpha subunits of sodium channels in a mammalian cell line. J. Biol. Chem. 270,
3306–3312.
James, W. M., and Agnew, W. S. (1987). Multiple oligosaccharide chains in the
voltage-sensitive Na channel from Electrophorus electricus: evidence for α-
2,8-linked polysialic acid. Biochem. Biophys. Res. Commun. 148, 817–826. doi:
10.1016/0006-291x(87)90949-1
Jarecki, B. W., Piekarz, A. D., Jackson, J. O. II, and Cummins, T. R. (2010). Human
voltage-gated sodium channel mutations that cause inherited neuronal and
muscle channelopathies increase resurgent sodium currents. J. Clin. Invest. 120,
369–378. doi: 10.1172/JCI40801
Jarvis, M. F., Honore, P., Shieh, C.-C., Chapman, M., Joshi, S., Zhang, X.-F.,
et al. (2007). A-803467, a potent and selective Nav1.8 sodium channel blocker,
attenuates neuropathic and inﬂammatory pain in the rat. Proc. Natl. Acad. Sci.
104, 8520–8525. doi: 10.1073/pnas.0611364104
Ji, R. R., Gereau Iv, R. W., Malcangio, M., and Strichartz, G. R. (2009). MAP kinase
and pain. Brain Res. Rev. 60, 135–148. doi: 10.1016/j.brainresrev.2008.12.011
Ji, R. R., Kawasaki, Y., Zhuang, Z. Y., Wen, Y. R., and Zhang, Y. Q. (2007). “Protein
kinases as potential targets for the treatment of pathological pain,” in Analgesia,
ed. C. Stein (Berlin: Springer), 359–389.
Jin, X., and Gereau, R. (2006). Acute p38-mediated modulation of tetrodotoxin-
resistant sodium channels in mouse sensory neurons by tumor necrosis factor-
alpha. J. Neurosci. 26, 246–255.
Joazeiro, C. A., and Weissman, A. M. (2000). RING ﬁnger proteins: mediators
of ubiquitin ligase activity. Cell 102, 549–552. doi: 10.1016/S0092-8674(00)
00077-5
Johnson, D., and Bennett, E. S. (2006). Isoform-speciﬁc eﬀects of the β2 Subunit
on voltage-gated sodium channel gating. J. Biol. Chem. 281, 25875–25881. doi:
10.1074/jbc.M605060200
Johnson, D., Montpetit, M. L., Stocker, P. J., and Bennett, E. S. (2004). The sialic
acid component of the β1 subunit modulates voltage-gated sodium channel
function. J. Biol. Chem. 279, 44303–44310. doi: 10.1074/jbc.M408900200
Joshi, S. K., Mikusa, J. P., Hernandez, G., Baker, S., Shieh, C. C., Neelands, T.,
et al. (2006). Involvement of the TTX-resistant sodium channel Nav 1.8 in
inﬂammatory and neuropathic, but not post-operative, pain states. Pain 123,
75–82.
Julius, D., and Basbaum, A. I. (2001). Molecular mechanisms of nociception.
Nature 413, 203–210.
Kazarinova-Noyes, K., Malhotra, J. D., Mcewen, D. P., Mattei, L. N., Berglund,
E. O., Ranscht, B., et al. (2001). Contactin associates with Na+ channels and
increases their functional expression. J. Neurosci. 21, 7517–7525.
Kazen-Gillespie, K. A., Ragsdale, D. S., D’Andrea, M. R., Mattei, L. N., Rogers,
K. E., and Isom, L. L. (2000). Cloning, localization, and functional expression
of sodium channel beta1A subunits. J. Biol. Chem. 275, 1079–1088. doi:
10.1074/jbc.275.2.1079
Kerr, B. J., Souslova, V., Mcmahon, S. B., and Wood, J. N. (2001). A role for the
TTX-resistant sodium channel Nav 1.8 in NGF-induced hyperalgesia, but not
neuropathic pain. NeuroReport 12, 3077–3080.
Khasar, S. G., Gold,M. S., and Levine, J. D. (1998). A tetrodotoxin-resistant sodium
current mediates inﬂammatory pain in the rat. Neurosci. Lett. 256, 17–20. doi:
10.1016/S0304-3940(98)00738-1
Khasar, S. G., Lin, Y., Martin, A., Dadgar, J., Mcmahon, T., Wang, D., et al. (1999).
A novel nociceptor signaling pathway revealed in protein kinase C epsilon
mutant mice. Neuron 24, 253–260.
Khasar, S. G., Ouseph, A. K., Chou, B., Ho, T., Green, P. G., and Levine,
J. D. (1995). Is there more than one prostaglandin E receptor subtype
mediating hyperalgesia in the rat hindpaw? Neuroscience 64, 1161–1165. doi:
10.1016/0306-4522(94)00423-3
Kim, E. K., and Choi, E.-J. (2010). Pathological roles of MAPK signaling
pathways in human diseases. Biochim. Biophys. Acta 1802, 396–405. doi:
10.1016/j.bbadis.2009.12.009
Frontiers in Pharmacology | www.frontiersin.org 15 November 2015 | Volume 6 | Article 263
Laedermann et al. Pain and post-translational modifications of sodium channels
Kispersky, T. J., Caplan, J. S., and Marder, E. (2012). Increase in sodium
conductance decreases ﬁring rate and gain in model neurons. J. Neurosci. 32,
10995–11004. doi: 10.1523/jneurosci.2045-12.2012
Klugbauer, N., Lacinova, L., Flockerzi, V., and Hofmann, F. (1995). Structure and
functional expression of a new member of the tetrodotoxin-sensitive voltage-
activated sodium-channel family from human neuroendocrine cells. EMBO J.
14, 1084–1090.
Kreegipuu, A., Blom, N., and Brunak, S. (1999). PhosphoBase, a database
of phosphorylation sites: release 2.0. Nucleic Acids Res. 27, 237–239. doi:
10.1093/nar/27.1.237
Kresge, N., Simoni, R. D., and Hill, R. L. (2006). The discovery of ubiquitin-
mediated proteolysis by Aaron Ciechanover, Avram Hershko, and Irwin Rose.
J. Biol. Chem. 281:e32.
Kress, M., Rödl, J., and Reeh, P. W. (1996). Stable analogues of cyclic AMP
but not cyclic GMP sensitize unmyelinated primary aﬀerents in rat skin to
heat stimulation but not to inﬂammatory mediators, in vitro. Neuroscience 74,
609–617. doi: 10.1016/0306-4522(96)00181-9
Kretschmer, T., Happel, L. T., England, J. D., Nguyen, D. H., Tiel, R. L., Beuerman,
R. W., et al. (2002). Clinical article accumulation of PN1 and PN3 sodium
channels in painful human neuroma-evidence from immunocytochemistry.
Acta Neurochir. 144, 803–810. doi: 10.1007/s00701-002-0970-1
Kruger, L., Light, A., and Schweizer, F. (2003). Axonal terminals of sensory
neurons and their morphological diversity. J. Neurocytol. 32, 205–216. doi:
10.1023/B:NEUR.0000010080.62031.f0
Laedermann, C. J., Cachemaille, M., Kirschmann, G., Pertin, M., Gosselin, R. D.,
Chang, I., et al. (2013a). Dysregulation of voltage-gated sodium channels by
ubiquitin ligase NEDD4-2 in neuropathic pain. J. Clin. Invest. 123, 3002–3013.
doi: 10.1172/JCI68996
Laedermann, C. J., Syam, N., Pertin, M., Decosterd, I., and Abriel, H. (2013b).
beta1- and beta3- voltage-gated sodium channel subunits modulate cell surface
expression and glycosylation of Nav1.7 in HEK293 cells. Front. Cell Neurosci.
7:137. doi: 10.3389/fncel.2013.00137
Laedermann, C. J., Decosterd, I., and Abriel, H. (2014a). “Ubiquitylation of voltage-
gated sodium channels,” in Voltage Gated Sodium Channels, ed. P. C. Ruben
(Berlin: Springer), 231–250.
Laedermann, C. J., Pertin, M., Suter, M., and Decosterd, I. (2014b). Voltage-gated
sodium channel expression in mouse DRG after SNI leads to re-evaluation of
projections of injured ﬁbers.Mol. Pain 10:19.
Lai, J., Gold, M. S., Kim, C. S., Bian, D., Ossipov, M. H., Hunter, J. C., et al. (2002).
Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-
resistant sodium channel, NaV1.8. Pain 95, 143–152. doi: 10.1016/s0304-
3959(01)00391-8
Latremoliere, A., and Woolf, C. J. (2009). Central sensitization: a generator of
pain hypersensitivity by central neural plasticity. J. Pain 10, 895–926. doi:
10.1016/j.jpain.2009.06.012
Leipold, E., Liebmann, L., Korenke, G. C., Heinrich, T., Gieszelmann, S., Baets, J.,
et al. (2013). A de novo gain-of-function mutation in SCN11A causes loss of
pain perception.Nat. Genet. 45, 1399–1404. doi: 10.1038/ng.2767
Leo, S., D’Hooge, R., and Meert, T. (2010). Exploring the role of nociceptor-speciﬁc
sodium channels in pain transmission using Nav1.8 and Nav1.9 knockout mice.
Behav. Brain Res. 208, 149–157. doi: 10.1016/j.bbr.2009.11.023
Leung, L., and Cahill, C. (2010). TNF-alpha and neuropathic pain - a review.
J. Neuroinﬂamm. 7:27.
Li, M., West, J. W., Lai, Y., Scheuer, T., and Catterall, W. A. (1992). Functional
modulation of brain sodium channels by cAMP-dependent phosphorylation.
Neuron 8, 1151–1159. doi: 10.1016/0896-6273(92)90135-Z
Liang, L., Fan, L., Tao, B., Yaster, M., and Tao, Y.-X. (2013). Protein kinase
B/Akt is required for complete freund’s adjuvant-induced upregulation of
Nav1.7 and Nav1.8 in primary sensory neurons. J. Pain 14, 638–647. doi:
10.1016/j.jpain.2013.01.778
Liu, C., Cao, J., Ren, X., and Zang, W. (2012). Na(v)1.7 protein and mRNA
expression in the dorsal root ganglia of rats with chronic neuropathic pain.
Neural Regen. Res. 7, 1540–1544. doi: 10.3969/j.issn.1673-5374.2012.20.003
Liu, C., Li, Q., Su, Y., and Bao, L. (2010). Prostaglandin E2 promotes Nav1.8
traﬃcking via its intracellular RRRMotif through the protein kinase A pathway.
Traﬃc 11, 405–417. doi: 10.1111/j.1600-0854.2009.01027.x
Liu, C.-N., Wall, P. D., Ben-Dor, E., Michaelis, M., Amir, R., and Devor, M.
(2000). Tactile allodynia in the absence of C-ﬁber activation: altered ﬁring
properties of DRG neurons following spinal nerve injury. Pain 85, 503–521.
doi: 10.1016/S0304-3959(00)00251-7
Liu, M., and Wood, J. N. (2011). The roles of sodium channels in nociception:
implications for mechanisms of neuropathic pain. Pain. Med. 12(Suppl. 3),
S93–S99. doi: 10.1111/j.1526-4637.2011.01158.x
Liu, S., and Zheng, P. (2013). Altered PKA modulation in the Na(v)1.1 epilepsy
variant I1656M. J. Neurophysiol. 110, 2090–2098.
Lolignier, S., Amsalem, M., Maingret, F., Padilla, F., Gabriac, M., Chapuy, E.,
et al. (2011). Nav1.9 channel contributes to mechanical and heat pain
hypersensitivity induced by subacute and chronic inﬂammation. PLoS ONE
6:e23083. doi: 10.1371/journal.pone.0023083
Lopez-Santiago, L. F., Brackenbury, W. J., Chen, C., and Isom, L. L. (2011).
Na+ channel scn1b gene regulates dorsal root ganglion nociceptor excitability
in vivo. J. Biol. Chem. 286, 22913–22923. doi: 10.1074/jbc.M111.242370
Lopez-Santiago, L. F., Pertin, M., Morisod, X., Chen, C., Hong, S., Wiley, J., et al.
(2006). Sodium channel beta2 subunits regulate tetrodotoxin-sensitive sodium
channels in small dorsal root ganglion neurons and modulate the response to
pain. J. Neurosci. 26, 7984–7994. doi: 10.1523/JNEUROSCI.2211-06.2006
Lou, J.-Y., Laezza, F., Gerber, B. R., Xiao, M., Yamada, K. A., Hartmann, H.,
et al. (2005). Fibroblast growth factor 14 is an intracellular modulator of
voltage-gated sodium channels. J. Physiol. 569, 179–193. doi: 10.1113/jphysiol.
2005.097220
Luo, F., Yang, C., Chen, Y., Shukla, P., Tang, L., Wang, L. X., et al. (2008a). Reversal
of chronic inﬂammatory pain by acute inhibition of Ca2+/Calmodulin-
dependent protein kinase II. J. Pharmacol. Exp. Ther. 325, 267–275. doi:
10.1124/jpet.107.132167
Luo, S., Perry, G., Levinson, S. R., and Henry, M. (2008b). Nav1.7 expression is
increased in painful human dental pulp.Molecular Pain 4:16.
Maingret, F., Coste, B., Padilla, F., Clerc, N., Crest, M., Korogod, S., et al. (2008).
Inﬂammatory mediators increase Nav1.9 current and excitability in nociceptors
through a coincident detection mechanism. J. Gen. Physiol. 131, 211–225.
Malhotra, J. D., Kazen-Gillespie, K., Hortsch, M., and Isom, L. L. (2000). Sodium
channel +Ý subunits mediate homophilic cell adhesion and recruit ankyrin to
points of cell-cell contact. J. Biol. Chem. 275, 11383–11388.
Malhotra, J. D., Koopmann, M. C., Kazen-Gillespie, K. A., Fettman, N.,
Hortsch, M., and Isom, L. L. (2002). Structural requirements for interaction of
sodium channel β1 subunits with ankyrin. J. Biol. Chem. 277, 26681–26688. doi:
10.1074/jbc.M202354200
Maltsev, V. A., Reznikov, V., Undrovinas, N. A., Sabbah, H. N., and Undrovinas, A.
(2008). Modulation of late sodium current by Ca2+, calmodulin, and CaMKII
in normal and failing dog cardiomyocytes: similarities and diﬀerences. Am. J.
Physiol. Heart Circ. Physiol. 294, H1597–H1608.
Mann, M., and Jensen, O. N. (2003). Proteomic analysis of post-translational
modiﬁcations. Nat. Biotech. 21, 255–261.
Mao, J., and Chen, L. L. (2000). Systemic lidocaine for neuropathic pain relief. Pain
87, 7–17. doi: 10.1016/s0304-3959(00)00229-3
Matzner, O., and Devor, M. (1992). Na+ conductance and the threshold
for repetitive neuronal ﬁring. Brain Res. 597, 92–98. doi: 10.1016/0006-
8993(92)91509-D
Matzner, O., and Devor, M. (1994). Hyperexcitability at sites of nerve injury
depends on voltage-sensitive Na+ channels. J. Neurophysiol. 72, 349–359.
Messner, D. J., and Catterall, W. A. (1985). The sodium channel from rat brain.
Separation and characterization of subunits. J. Biol. Chem. 260, 10597–10604.
Metzger, M. B., Hristova, V. A., and Weissman, A. M. (2012). HECT and RING
ﬁnger families of E3 ubiquitin ligases at a glance. J. Cell Sci. 125, 531–537. doi:
10.1242/jcs.091777
Millan, M. J. (1999). The induction of pain: an integrative review. Prog. Neurobiol.
57, 1–164. doi: 10.1016/s0301-0082(98)00048-3
Minett, M., Nassar, M., Clark, A., Passmore, G., Dickenson, A., Wang, F., et al.
(2012). Distinct Nav1.7-dependent pain sensations require diﬀerent sets of
sensory and sympathetic neurons. Nat. Commun. 3:791.
Mittmann, T., and Alzheimer, C. (1998). Muscarinic inhibition of persistent Na+
current in rat neocortical pyramidal neurons. J. Physiol. 535(Pt 2), 383–396.
Moon, J.-Y., Song, S., Yoon, S.-Y., Roh, D.-H., Kang, S.-Y., Park, J.-H.,
et al. (2012). The diﬀerential eﬀect of intrathecal Nav1.8 blockers on the
induction and maintenance of capsaicin- and peripheral ischemia-induced
mechanical allodynia and thermal hyperalgesia. Anesth. Analg. 114, 215–223.
doi: 10.1213/ANE.0b013e318238002e
Frontiers in Pharmacology | www.frontiersin.org 16 November 2015 | Volume 6 | Article 263
Laedermann et al. Pain and post-translational modifications of sodium channels
Moremen, K. W., Tiemeyer, M., and Nairn, A. V. (2012). Vertebrate protein
glycosylation: diversity, synthesis and function. Nat. Rev. Mol. Cell Biol. 13,
448–462.
Morgan, K., Stevens, E. B., Shah, B., Cox, P. J., Dixon, A. K., Lee, K., et al. (2000).
β3: an additional auxiliary subunit of the voltage-sensitive sodium channel that
modulates channel gating with distinct kinetics. Proc. Natl. Acad. Sci. U.S.A. 97,
2308–2313. doi: 10.1073/pnas.030362197
Mori, M., Konno, T., Ozawa, T., Murata, M., Imoto, K., and Nagayama, K.
(2000). Novel interaction of the voltage-dependent sodium channel (VDSC)
with calmodulin: does VDSC acquire calmodulin-mediated Ca2+-Sensitivity.
Biochemistry 39, 1316–1323. doi: 10.1021/bi9912600
Murphy, B. J., Rossie, S., De Jongh, K. S., and Catterall, W. A. (1993). Identiﬁcation
of the sites of selective phosphorylation and dephosphorylation of the rat
brain Na+ channel α subunit by cAMP-dependent protein kinase and
phosphoprotein phosphatases. J. Biol. Chem. 268, 27355–27362.
Murray, K. T., Hu, N. N., Daw, J. R., Shin, H. G., Watson, M. T., Mashburn, A. B.,
et al. (1997). Functional eﬀects of protein kinase C activation on the human
cardiac Na+ channel. Circ. Res. 80, 370–376.
Nagasako, E. M., Oaklander, A. L., and Dworkin, R. H. (2003). Congenital
insensitivity to pain: an update. Pain 101, 213–219. doi: 10.1016/s0304-
3959(02)00482-7
Narayanan, A., and Jacobson, M. P. (2009). Computational studies of protein
regulation by post-translational phosphorylation. Curr. Opin. Struct. Biol. 19,
156–163. doi: 10.1016/j.sbi.2009.02.007
Nassar, M., Stirling, L., Forlani, G., Baker, M., Matthews, E., Dickenson, A.,
et al. (2004). Nociceptor-speciﬁc gene deletion reveals a major role for Nav1.7
(PN1) in acute and inﬂammatory pain. Proc. Natl. Acad. Sci. U.S.A. 101,
12706–12711.
Nelson, M. R., and Chazin, W. J. (1998). An interaction-based analysis of calcium-
induced conformational changes in Ca2+ sensor proteins. Protein Sci. 7,
270–282. doi: 10.1002/pro.5560070206
Noda, M., and Hiyama, T. Y. (2014). The nax channel: what it is and what it does.
Neuroscientist 21, 399–412. doi: 10.1177/1073858414541009
Novella, S. P., Hisama, F. M., Dib-Hajj, S. D., and Waxman, S. G. (2007). A case of
inherited erythromelalgia. Nat. Clin. Pract. Neurol. 3, 229–234.
Numann, R., Catterall, W. A., and Scheuer, T. (1991). Functional modulation
of brain sodium channels by protein kinase C phosphorylation. Science 254,
115–118.
Nuss, H. B., Chiamvimonvat, N., Perez-Garcia, M. T., Tomaselli, G. F., and
Marban, E. (1995). Functional association of the beta 1 subunit with
human cardiac (hH1) and rat skeletal muscle (mu 1) sodium channel alpha
subunits expressed in Xenopus oocytes. J. Gen. Physiol. 106, 1171–1191. doi:
10.1085/jgp.106.6.1171
Obata, K., and Noguchi, K. (2004). MAPK activation in nociceptive neurons and
pain hypersensitivity. Life Sci. 74, 2643–2653. doi: 10.1016/j.lfs.2004.01.007
Olsson, Y. (1967). Degranulation of mast cells in peripheral nerve injuries. Acta
Neurol. Scand. 43, 365–374.
Payandeh, J., Scheuer, T., Zheng, N., and Catterall, W. A. (2011). The crystal
structure of a voltage-gated sodium channel. Nature 475, 353–358. doi:
10.1038/nature10238
Perry, V. H., Brown, M. C., and Gordon, S. (1987). The macrophage response
to central and peripheral nerve injury. A possible role for macrophages in
regeneration. J. Exp. Med. 165, 1218–1223. doi: 10.1084/jem.165.4.1218
Persson, A., Gasser, A., Black, J., and Waxman, S. (2011). Nav1.7 accumulates
and co-localizes with phosphorylated ERK1/2 within transected axons in early
experimental neuromas. Exp. Neurol. 230, 273–279.
Pertin, M., Ji, R., Berta, T., Powell, A., Karchewski, L., Tate, S., et al. (2005).
Upregulation of the voltage-gated sodium channel beta2 subunit in neuropathic
pain models: characterization of expression in injured and non-injured primary
sensory neurons. J. Neurosci. 25, 10970–10980.
Petho, G., and Reeh, P. W. (2012). Sensory and signaling mechanisms
of bradykinin, eicosanoids, platelet-activating factor, and nitric oxide in
peripheral nociceptors. Physiol. Rev. 92, 1699–1775. doi: 10.1152/physrev.
00048.2010
Pickart, C.M. (2001).Mechanisms underlying ubiquitination.Annu. Rev. Biochem.
70, 503–533. doi: 10.1146/annurev.biochem.70.1.503
Pierre, S., Eschenhagen, T., Geisslinger, G., and Scholich, K. (2009). Capturing
adenylyl cyclases as potential drug targets. Nat. Rev. Drug Discov. 8, 321–335.
Pitchford, S., and Levine, J. D. (1991). Prostaglandins sensitize nociceptors in cell
culture. Neurosci. Lett. 132, 105–108.
Plummer, N. W., Mcburney, M.W., andMeisler, M. H. (1997). Alternative splicing
of the sodium channel SCN8A predicts a truncated two-domain protein in
fetal brain and non-neuronal cells. J. Biol. Chem. 272, 24008–24015. doi:
10.1074/jbc.272.38.24008
Priest, B. T., Murphy, B. A., Lindia, J. A., Diaz, C., Abbadie, C., Ritter,
A. M., et al. (2005). Contribution of the tetrodotoxin-resistant voltage-
gated sodium channel NaV1.9 to sensory transmission and nociceptive
behavior. Proc. Natl. Acad. Sci. U.S.A. 102, 9382–9387. doi: 10.1073/pnas.0501
549102
Qu, Y., Rogers, J., Tanada, T., Scheuer, T., and Catterall, W. A. (1994). Modulation
of cardiac Na+ channels expressed in a mammalian cell line and in ventricular
myocytes by protein kinase C. Proc. Natl. Acad. Sci. U.S.A. 91, 3289–3293.
Rang, H., and Ritchie, J. (1988). Depolarization of nonmyelinated ﬁbers of the
rat vagus nerve produced by activation of protein kinase C. J. Neurosci. 8,
2606–2617.
Ranscht, B. (1988). Sequence of contactin, a 130-kD glycoprotein concentrated in
areas of interneuronal contact, deﬁnes a new member of the immunoglobulin
supergene family in the nervous system. J. Cell Biol. 107, 1561–1573. doi:
10.1083/jcb.107.4.1561
Raymond, C. K., Castle, J., Garrett-Engele, P., Armour, C. D., Kan, Z.,
Tsinoremas, N., et al. (2004). Expression of alternatively spliced sodium channel
α-subunit genes: unique splicing patterns are observed in dorsal root ganglia.
J. Biol. Chem. 279, 46234–46241. doi: 10.1074/jbc.M406387200
Recio-Pinto, E., Thornhill, W. B., Duch, D. S., Levinson, S. R., and Urban,
B. W. (1990). Neuraminidase treatment modiﬁes the function of electroplax
sodium channels in planar lipid bilayers.Neuron 5, 675–684. doi: 10.1016/0896-
6273(90)90221-z
Ren, D., Navarro, B., Xu, H., Yue, L., Shi, Q., and Clapham, D. E. (2001).
A prokaryotic voltage-gated sodium channel. Science 294, 2372–2375. doi:
10.1126/science.1065635
Renganathan, M., Dib-Hajj, S., and Waxman, S. G. (2002). Nav1.5 underlies the
‘third TTX-R sodium current’ in rat small DRG neurons. Mol. Brain Res. 106,
70–82. doi: 10.1016/s0169-328x(02)00411-4
Renganathan, M., Godoy, C. M., and Cukierman, S. (1995). Direct modulation
of Na+ currents by protein kinase C activators in mouse neuroblastoma cells.
J. Membr. Biol. 144, 59–69.
Ritchie, J. M., Black, J. A., Waxman, S. G., and Angelides, K. J. (1990). Sodium
channels in the cytoplasm of Schwann cells. Proc. Natl. Acad. Sci. U.S.A. 87,
9290–9294.
Rossie, S., and Catterall, W. A. (1987). Cyclic-AMP-dependent phosphorylation
of voltage-sensitive sodium channels in primary cultures of rat brain neurons.
J. Biol. Chem. 262, 12735–12744.
Rossier, B. C., Pradervand, S., Schild, L., and Hummler, E. (2002). Epithelial
sodium channel and the control of sodium balance: interaction between
genetic and environmental factors. Annu. Rev. Physiol. 64, 877–897. doi:
10.1146/annurev.physiol.64.082101.143243
Rush, A. M., Cummins, T., and Waxman, S. (2007). Multiple sodium channels and
their roles in electrogenesis within dorsal root ganglion neurons. J. Physiol. 579,
1–14.
Rush, A. M., Dib-Hajj, S. D., Liu, S., Cummins, T. R., Black, J. A., and
Waxman, S. G. (2006). A single sodium channel mutation produces hyper- or
hypoexcitability in diﬀerent types of neurons. Proc. Natl. Acad. Sci. U.S.A. 103,
8245–8250.
Rush, A. M., and Waxman, S. G. (2004). PGE2 increases the tetrodotoxin-resistant
Nav1.9 sodium current in mouse DRG neurons via G-proteins. Brain Res. 1023,
264–271. doi: 10.1016/j.brainres.2004.07.042
Sadamasu, A., Sakuma, Y., Suzuki, M., Orita, S., Yamauchi, K., Inoue, G., et al.
(2014). Upregulation of NaV1.7 in dorsal root ganglia after intervertebral
disc injury in rats. Spine 39, E421–E426. doi: 10.1097/brs.00000000000
00229
Sangameswaran, L., Fish, L. M., Koch, B. D., Rabert, D. K., Delgado, S. G.,
Ilnicka, M., et al. (1997). A novel tetrodotoxin-sensitive, voltage-gated sodium
channel expressed in rat and human dorsal root ganglia. J. Biol. Chem. 272,
14805–14809.
Sanna, P. P., Cammalleri,M., Berton, F., Simpson, C., Lutjens, R., Bloom, F. E., et al.
(2002). Phosphatidylinositol 3-Kinase is required for the expression but not for
Frontiers in Pharmacology | www.frontiersin.org 17 November 2015 | Volume 6 | Article 263
Laedermann et al. Pain and post-translational modifications of sodium channels
the induction or the maintenance of long-term potentiation in the hippocampal
CA1 region. J. Neurosci. 22, 3359–3365.
Schaller, K. L., Krzemien, D. M., Mckenna, N. M., and Caldwell, J. H.
(1992). Alternatively spliced sodium channel transcripts in brain and muscle.
J. Neurosci. 12, 1370–1381.
Schepelmann, K., Messlinger, K., and Schmidt, R. F. (1993). The eﬀects of phorbol
ester on slowly conducting aﬀerents of the cat’s knee joint. Exp. Brain Res. 92,
391–398.
Schild, L., Lu, Y., Gautschi, I., Schneeberger, E., Lifton, R. P., and Rossier, B. C.
(1996). Identiﬁcation of a PY motif in the epithelial Na channel subunits as
a target sequence for mutations causing channel activation found in Liddle
syndrome. EMBO J. 15, 2381–2387.
Schirmeyer, J., Szafranski, K., Leipold, E., Mawrin, C., Platzer, M., and Heinemann,
S. H. (2014). Exon 11 skipping of SCN10A coding for voltage-gated
sodium channels in dorsal root ganglia. Channels 8, 210–215. doi: 10.4161/
chan.28146
Schmidt, J., Rossie, S., and Catterall, W. A. (1985). A large intracellular pool of
inactive Na channel alpha subunits in developing rat brain. Proc. Natl. Acad.
Sci. U.S.A. 82, 4847–4851.
Schmidt, J. W., and Catterall, W. A. (1987). Palmitylation, sulfation, and
glycosylation of the alpha subunit of the sodium channel. Role of post-
translational modiﬁcations in channel assembly. J. Biol. Chem. 262, 13713–
13723.
Scholz, J., Broom, D. C., Youn, D. H., Mills, C. D., Kohno, T., Suter, M. R., et al.
(2005). Blocking caspase activity prevents transsynaptic neuronal apoptosis and
the loss of inhibition in lamina ii of the dorsal horn after peripheral nerve injury.
J. Neurosci. 25, 7317–7323.
Shah, B. S., Stevens, E. B., Gonzalez,M. I., Bramwell, S., Pinnock, R. D., Lee, K., et al.
(2000). beta3, a novel auxiliary subunit for the voltage-gated sodium channel,
is expressed preferentially in sensory neurons and is upregulated in the chronic
constriction injury model of neuropathic pain. Euro. J. Neurosci. 12, 3985–3990.
doi: 10.1046/j.1460-9568.2000.00294.x
Shao, D., Okuse, K., and Djamgoz, M. B. A. (2009). Protein–protein
interactions involving voltage-gated sodium channels: post-translational
regulation, intracellular traﬃcking and functional expression. Int.
J. Biochem. Cell Biol. 41, 1471–1481. doi: 10.1016/j.biocel.2009.0
1.016
Shi, T. J. S., Huang, P., Mulder, J., Ceccatelli, S., and Hökfelt, T. (2009). Expression
of p-Akt in sensory neurons and spinal cord after peripheral nerve injury.
Neurosignals 17, 203–212.
Shih, S. C., Sloper-Mould, K. E., and Hicke, L. (2000). Monoubiquitin carries a
novel internalization signal that is appended to activated receptors. EMBO J.
19, 187–198. doi: 10.1093/emboj/19.2.187
Smith, R. D., and Goldin, A. L. (1996). Phosphorylation of brain sodium channels
in the I-II linker modulates channel function inXenopus oocytes. J. Neurosci. 16,
1965–1974.
Smith, R. D., and Goldin, A. L. (1998). Functional analysis of the rat I sodium
channel in Xenopus oocytes. J. Neurosci. 18, 811–820.
Snyder, P. M. (2009). Down-regulating destruction: phosphorylation regulates
the E3 ubiquitin ligase NEDD4-2. Sci. Signal. 2:pe41. doi: 10.1126/scisignal.
279pe41
Snyder, P. M., Olson, D. R., Kabra, R., Zhou, R., and Steines, J. C. (2004). cAMP
and serum and glucocorticoid-inducible kinase (SGK) regulate the epithelial
Na+ channel through convergent phosphorylation of NEDD4-2. J. Biol. Chem.
279, 45753–45758. doi: 10.1074/jbc.M407858200
Solà, C., Barrón, S., Tusell, J. M., and Serratosa, J. (2001). The Ca2+/calmodulin
system in neuronal hyperexcitability. Int. J. Biochem. Cell Biol. 33, 439–455. doi:
10.1016/S1357-2725(01)00030-9
Souza, A. L. S., Moreira, F. A., Almeida, K. R., Bertollo, C. M., Costa, K. A.,
and Coelho, M. M. (2002). In vivo evidence for a role of protein kinase
C in peripheral nociceptive processing. Br. J. Pharmacol. 135, 239–247. doi:
10.1038/sj.bjp.0704434
Stamboulian, S., Choi, J., Ahn, H., Chang, Y., Tyrrell, L., Black, J., et al. (2010).
ERK1/2 mitogen-activated protein kinase phosphorylates sodium channel
Na(v)1.7 and alters its gating properties. J. Neurosci. 30, 1637–1647.
Staub, O., and Rotin, D. (2006). Role of ubiquitylation in cellular membrane
transport. Physiol. Rev. 86, 669–707. doi: 10.1152/physrev.00020.2005
Strickland, I. T., Martindale, J. C., Woodhams, P. L., Reeve, A. J., Chessell, I. P.,
and Mcqueen, D. S. (2008). Changes in the expression of NaV1.7, NaV1.8 and
NaV1.9 in a distinct population of dorsal root ganglia innervating the rat knee
joint in a model of chronic inﬂammatory joint pain. Euro. J. Pain 12, 564–572.
doi: 10.1016/j.ejpain.2007.09.001
Stucky, C. L., Dubin, A. E., Jeske, N. A., Malin, S. A., Mckemy, D. D., and Story,
G. M. (2009). Roles of transient receptor potential channels in pain. Brain Res.
Rev. 60, 2–23. doi: 10.1016/j.brainresrev.2008.12.018
Sun, R.-Q., Tu, Y.-J., Yan, J.-Y., and Willis, W. D. (2006). Activation of protein
kinase B/Akt signaling pathway contributes to mechanical hypersensitivity
induced by capsaicin. Pain 120, 86–96. doi: 10.1016/j.pain.2005.
10.017
Suter, M. R., Papaloïzos, M., Berde, C. B., Woolf, C. J., Gilliard, N., Spahn,
D. R., et al. (2003). Development of neuropathic pain in the rat spared nerve
injury model is not prevented by a peripheral nerve block. Anesthesiology 99,
1402–1408.
Taiwo, Y. O., Bjerknes, L. K., Goetzl, E. J., and Levine, J. D. (1989). Mediation
of primary aﬀerent peripheral hyperalgesia by the cAMP second messenger
system. Neuroscience 32, 577–580.
Tan, Z.-Y., Priest, B. T., Krajewski, J. L., Knopp, K. L., Nisenbaum, E. S., and
Cummins, T. R. (2014). Protein kinase C enhances human sodium channel
hNav1.7 resurgent currents via a serine residue in the domain III–IV linker.
FEBS Lett. 588, 3964–3969. doi: 10.1016/j.febslet.2014.09.011
Thakor, D., Lin, A., Matsuka, Y., Meyer, E., Ruangsri, S., Nishimura, I., et al. (2009).
Increased peripheral nerve excitability and local NaV1.8 mRNA up-regulation
in painful neuropathy.Mol. Pain 5:14.
Theriault, O., and Chahine, M. (2014). Correlation of the electrophysiological
proﬁles and sodium channel transcripts of individual rat dorsal root ganglia
neurons. Front. Cell Neurosci. 8:285. doi: 10.3389/fncel.2014.00285
Thornalley, P. J. (2005). Dicarbonyl intermediates in the maillard reaction. Ann.
N. Y. Acad. Sci. 1043, 111–117. doi: 10.1196/annals.1333.014
Toledo-Aral, J. J., Brehm, P., Halegoua, S., and Mandel, G. (1995). A single
pulse of nerve growth factor triggers long-term neuronal excitability through
sodium channel gene induction. Neuron 14, 607–611. doi: 10.1016/0896-
6273(95)90317-8
Toledo-Aral, J. J., Moss, B. L., He, Z. J., Koszowski, A. G.,Whisenand, T., Levinson,
S. R., et al. (1997). Identiﬁcation of PN1, a predominant voltage-dependent
sodium channel expressed principally in peripheral neurons. Proc. Natl. Acad.
Sci. U.S.A. 94, 1527–1532.
Tong, S. E., Daniels, S. E., Black, P., Chang, S., Protter, A., and Desjardins, P. J.
(2012). Novel p38α mitogen-activated protein kinase inhibitor shows analgesic
eﬃcacy in acute postsurgical dental pain. J. Clin. Pharmacol. 52, 717–728. doi:
10.1177/0091270011405496
Toth, C., Lander, J., and Wiebe, S. (2009). The prevalence and impact of chronic
pain with neuropathic pain symptoms in the general population. Pain Med. 10,
918–929. doi: 10.1111/j.1526-4637.2009.00655.x
Turk, D. C., Audette, J., Levy, R. M., Mackey, S. C., and Stanos, S.
(2010). Assessment and treatment of psychosocial comorbidities in patients
with neuropathic pain. Mayo Clin. Proc. 85, S42–S50. doi: 10.4065/mcp.
2009.0648
Tyrrell, L., Renganathan, M., Dib-Hajj, S. D., and Waxman, S. G. (2001).
Glycosylation alters steady-state inactivation of sodium channel Nav1.9/nan in
dorsal root ganglion neurons and is developmentally regulated. J. Neurosci. 21,
9629–9637.
van Bemmelen, M. X., Rougier, J. S., Gavillet, B., Apotheloz, F., Daidie, D.,
Tateyama, M., et al. (2004). Cardiac voltage-gated sodium channel Nav1.5 is
regulated by NEDD4-2 mediated ubiquitination. Circ. Res. 95, 284–291.
Vanoye, C. G., Kunic, J. D., Ehring, G. R., and George, A. L. (2013). Mechanism
of sodium channel NaV1.9 potentiation by G-protein signaling. J. Gen. Physiol.
141, 193–202. doi: 10.1085/jgp.201210919
Vijayaragavan, K., Boutjdir, M., and Chahine, M. (2004a). Modulation of Nav1.7
and Nav1.8 peripheral nerve sodium channels by protein kinase A and protein
kinase C. J. Neurophysiol. 91, 1556–1569. doi: 10.1152/jn.00676.2003
Vijayaragavan, K., Powell, A. J., Kinghorn, I. J., and Chahine, M. (2004b). Role of
auxiliary beta1-, beta2-, and beta3-subunits and their interaction with Na(v)1.8
voltage-gated sodium channel. Biochem. Biophys. Res. Commun. 319, 531–540.
doi: 10.1016/j.bbrc.2004.05.026
Frontiers in Pharmacology | www.frontiersin.org 18 November 2015 | Volume 6 | Article 263
Laedermann et al. Pain and post-translational modifications of sodium channels
Vijayaragavan, K., O’Leary, M. E., and Chahine, M. (2001). Gating properties
of Nav1.7 and Nav1.8 peripheral nerve sodium channels. J. Neurosci. 21,
7909–7918.
von Hehn, C. A., Baron, R., and Woolf, C. J. (2012). Deconstructing the
neuropathic pain phenotype to reveal neural mechanisms. Neuron 73, 638–652.
doi: 10.1016/j.neuron.2012.02.008
Wada, A., Wanke, E., Gullo, F., and Schiavon, E. (2008). Voltage-dependent
Nav1.7 sodium channels: multiple roles in adrenal chromaﬃn cells and
peripheral nervous system. Acta Physiol. 192, 221–231. doi: 10.1111/j.1748-
1716.2007.01810.x
Wada, A., Yanagita, T., Yokoo, H., and Kobayashi, H. (2004). Regulation of
cell surface expression of voltage-dependent Nav1.7 sodium channels: mRNA
stability and posttranscriptional control in adrenal chromaﬃn cells. Front.
Biosci. 9:1954–1966. doi: 10.1371/journal.pone.0023083
Waechter, C. J., Schmidt, J. W., and Catterall, W. A. (1983). Glycosylation is
required formaintenance of functional sodium channels in neuroblastoma cells.
J. Biol. Chem. 258, 5117–5123.
Wang, Y., Brittain, J. M., Jarecki, B. W., Park, K. D., Wilson, S. M., Wang, B.,
et al. (2010). In silico docking and electrophysiological characterization
of lacosamide binding sites on collapsin response mediator Protein-
2 identiﬁes a pocket important in modulating sodium channel slow
inactivation. J. Biol. Chem. 285, 25296–25307. doi: 10.1074/jbc.M110.
128801
Waxman, S. G. (1999). The molecular pathophysiology of pain: abnormal
expression of sodium channel genes and its contributions to hyperexcitability
of primary sensory neurons. Pain 82, S133–S140. doi: 10.1016/s0304-
3959(99)00147-5
Waxman, S. G., and Dib-Hajj, S. (2005). Erythermalgia: molecular basis for an
inherited pain syndrome. Trends Mol. Med. 11, 555–562.
Waxman, S. G., Merkies, I. S. J., Gerrits, M. M., Dib-Hajj, S. D., Lauria, G., Cox,
J. J., et al. (2014). Sodium channel genes in pain-related disorders: phenotype–
genotype associations and recommendations for clinical use. Lancet Neurol. 13,
1152–1160. doi: 10.1016/S1474-4422(14)70150-4
Waxman, S. G., and Zamponi, G. W. (2014). Regulating excitability of peripheral
aﬀerents: emerging ion channel targets. Nat. Neurosci. 17, 153–163. doi:
10.1038/nn.3602
Way, K. J., Chou, E., and King, G. L. (2000). Identiﬁcation of PKC-isoform-speciﬁc
biological actions using pharmacological approaches. Trends Pharmacol. Sci. 21,
181–187. doi: 10.1016/S0165-6147(00)01468-1
Wells, M., Racis, S., and Vaidya, U. (1992). Changes in plasma cytokines associated
with peripheral nerve injury. J. Neuroimmunol. 39, 261–268.
Widmann, C., Gibson, S., Jarpe, M. B., and Johnson, G. L. (1999). Mitogen-
activated protein kinase: conservation of a three-kinase module from yeast to
human. Physiol. Rev. 79, 143–180.
Woolf, C. J. (2004). Dissecting out mechanisms responsible for peripheral
neuropathic pain: implications for diagnosis and therapy. Life Sci. 74, 2605–
2610. doi: 10.1016/j.lfs.2004.01.003
Woolf, C. J. (2011). Central sensitization: implications for the diagnosis
and treatment of pain. Pain 152, S2–S15. doi: 10.1016/j.pain.2010.
09.030
Woolf, C. J., and Costigan, M. (1999). Transcriptional and posttranslational
plasticity and the generation of inﬂammatory pain. Proc. Natl. Acad. Sci. U.S.A.
96, 7723–7730. doi: 10.1073/pnas.96.14.7723
Woolf, C. J., and Mannion, R. J. (1999). Neuropathic pain: aetiology, symptoms,
mechanisms, and management. Lancet 353, 1959–1964.
Woolf, C. J., and Salter, M. W. (2000). Neuronal plasticity: increasing the gain in
pain. Science 288, 1765–1768. doi: 10.1126/science.288.5472.1765
Wu, D.-F., Chandra, D., Mcmahon, T., Wang, D., Dadgar, J., Kharazia, V. N., et al.
(2012). PKCε phosphorylation of the sodium channel NaV1.8 increases channel
function and produces mechanical hyperalgesia in mice. J. Clin. Investig. 122,
1306–1315. doi: 10.1172/jci61934
Xu, J.-T., Tu, H.-Y., Xin, W.-J., Liu, X.-G., Zhang, G.-H., and Zhai, C.-H.
(2007a). Activation of phosphatidylinositol 3-kinase and protein kinase B/Akt
in dorsal root ganglia and spinal cord contributes to the neuropathic pain
induced by spinal nerve ligation in rats. Exp. Neurol. 206, 269–279. doi:
10.1016/j.expneurol.2007.05.029
Xu, J.-T., Xin, W.-J., Wei, X.-H., Wu, C.-Y., Ge, Y.-X., Liu, Y.-L., et al. (2007b).
p38 activation in uninjured primary aﬀerent neurons and in spinal microglia
contributes to the development of neuropathic pain induced by selective
motor ﬁber injury. Exp. Neurol. 204, 355–365. doi: 10.1016/j.expneurol.2006.
11.016
Xu, Q., Cheng, H.-W., He, H.-Q., Liu, Z.-R., He, M., Yang, H.-T., et al.
(2008). Deglycosylation altered the gating properties of rNav1.3:
glycosylation/deglycosylation homeostasis probably complicates the functional
regulation of voltage-gated sodium channel. Neurosci. Bull. 24, 283–287. doi:
10.1007/s12264-008-0524-5
Xu, Q., Fitzsimmons, B., Steinauer, J., Neill, A. O., Newton, A. C., Hua, X.-Y., et al.
(2011). Spinal phosphinositide 3-Kinase–Akt–Mammalian target of rapamycin
signaling cascades in inﬂammation-induced hyperalgesia. J. Neurosci. 31, 2113–
2124. doi: 10.1523/jneurosci.2139-10.2011
Yan, J., Melemedjian, O., Price, T., and Dussor, G. (2012). Sensitization of dural
aﬀerents underlies migraine-related behavior following meningeal application
of interleukin-6 (IL-6).Mol. Pain 8:6.
Yanagita, T., Kobayashi, H., Uezono, Y., Yokoo, H., Sugano, T., Saitoh, T.,
et al. (2003). Destabilization of Nav1.7 sodium channel α-subunit mRNA
by constitutive phosphorylation of extracellular signal-regulated kinase:
negative regulation of steady-state level of cell surface functional sodium
channels in adrenal chromaﬃn cells. Mol. Pharmacol. 63, 1125–1136. doi:
10.1124/mol.63.5.1125
Yanagita, T., Wada, A., Yamamoto, R., Kobayashi, H., Yuhi, T., Urabe, M., et al.
(1996). Protein kinase C-Mediated Down-Regulation of voltage-dependent
sodium channels in adrenal chromaﬃn cells. J. Neurochem. 66, 1249–1253. doi:
10.1046/j.1471-4159.1996.66031249.x
Yang, Y., Wang, Y., Li, S., Xu, Z., Li, H., Ma, L., et al. (2004). Mutations in
SCN9A, encoding a sodium channel alpha subunit, in patients with primary
erythermalgia. J. Med. Genet. 41, 171–174.
Yeomans, D. C., Levinson, S. R., Peters, M. C., Koszowski, A. G., Tzabazis,
A. Z., Gilly, W. F., et al. (2005). Decrease in inﬂammatory hyperalgesia
by herpes vector-mediated knockdown of Nav1.7 sodium channels in
primary aﬀerents. Hum. Gene Ther. 16, 271–277. doi: 10.1089/hum.2005.
16.271
Yin, R., Liu, D., Chhoa, M., Li, C. M., Luo, Y., Zhang, M., et al.
(2015). Voltage-gated sodium channel function and expression in injured
and uninjured rat dorsal root ganglia neurons. Int. J. Neurosci. doi:
10.3109/00207454.2015.1004172 [Epub ahead of print].
Young, K. A., and Caldwell, J. H. (2005). Modulation of skeletal and cardiac
voltage-gated sodium channels by calmodulin. J. Physiol. 565, 349–370. doi:
10.1113/jphysiol.2004.081422
Yu, F. H., Westenbroek, R. E., Silos-Santiago, I., Mccormick, K. A., Lawson, D.,
Ge, P., et al. (2003). Sodium channel β4, a new disulﬁde-linked auxiliary subunit
with similarity to β2. J. Neurosci. 23, 7577–7585.
Yu, Y.-Q., Zhao, F., Guan, S.-M., and Chen, J. (2011). Antisense-mediated
knockdown of Nav1.8, but Not Nav1.9, generates inhibitory eﬀects on complete
freund’s adjuvant-induced inﬂammatory pain in rat. PLoS ONE 6:e19865. doi:
10.1371/journal.pone.0019865
Yuhi, T., Wada, A., Yamamoto, R., Yanagita, T., Niina, H., and Niina, H. (1996).
Up-regulation of functional voltage-dependent sodium channels by cyclic
AMP-dependent protein kinase in adrenal medulla. Brain Res. 709, 37–43. doi:
10.1016/0006-8993(95)01252-4
Zhang, H., Cang, C., Kawasaki, Y., Liang, L., Zhang, Y., Ji, R., et al. (2007).
Neurokinin-1 receptor enhances TRPV1 activity in primary sensory neurons
via PKCepsilon: a novel pathway for heat hyperalgesia. J. Neurosci. 27, 12067–
12077.
Zhang, J. M., Donnelly, D. F., Song, X. J., and Lamotte, R. H. (1997). Axotomy
increases the excitability of dorsal root ganglion cells with unmyelinated axons.
J. Neurophysiol. 78, 2790–2794.
Zhang, X. y., Wen, J., Yang, W., Wang, C., Gao, L., Zheng, L. H., et al. (2013). Gain-
of-function mutations in SCN11A cause familial episodic pain. Am. J. Hum.
Genet. 93, 957–966. doi: 10.1016/j.ajhg.2013.09.016
Zhang, Y., Hartmann, H. A., and Satin, J. (1999). Glycosylation inﬂuences voltage-
dependent gating of cardiac and skeletal muscle sodium channels. J. Membr.
Biol. 171, 195–207.
Zhou, J., Shin, H.-G., Yi, J., Shen, W., Williams, C. P., and Murray, K. T. (2002).
Phosphorylation and putative ER retention signals are required for protein
kinase A-mediated potentiation of cardiac sodium current. Circ. Res. 91, 540–
546. doi: 10.1161/01.res.0000033598.00903.27
Frontiers in Pharmacology | www.frontiersin.org 19 November 2015 | Volume 6 | Article 263
Laedermann et al. Pain and post-translational modifications of sodium channels
Zhou, J., Yi, J., Hu, N., George, A. L., and Murray, K. T. (2000). Activation
of protein kinase A modulates traﬃcking of the human cardiac sodium
channel in Xenopus Oocytes. Circ. Res. 87, 33–38. doi: 10.1161/01.res.
87.1.33
Zhuang, Z.-Y., Xu, H., Clapham, D. E., and Ji, R.-R. (2004). Phosphatidylinositol 3-
Kinase activates ERK in primary sensory neurons and mediates inﬂammatory
heat hyperalgesia through TRPV1 sensitization. J. Neurosci. 24, 8300–8309. doi:
10.1523/jneurosci.2893-04.2004
Zimmer, T., and Benndorf, K. (2002). The human heart and rat brain IIA Na+
channels interact with diﬀerent molecular regions of the beta1 subunit. J. Gen.
Physiol. 120, 887–895. doi: 10.1085/jgp.20028703
Zochodne, D. W., Nguyen, C., and Sharkey, K. A. (1994).
Accumulation and degranulation of mast cells in experimental
neuromas. Neurosci. Lett. 182, 3–6. doi: 10.1016/0304-3940(94)90
191-0
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or ﬁnancial relationships that could
be construed as a potential conﬂict of interest.
Copyright © 2015 Laedermann, Abriel and Decosterd. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 20 November 2015 | Volume 6 | Article 263
